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Purpose: To determine if the IGF1 (CA) 19 repeat polymorphism influences muscle 
power at baseline and in response to strength training (ST) in older adults.  
Methods: Knee extensor (KE) peak power (PP) was measured at 50, 60, and 70% of 
1 RM strength before and after 10 wks of unilateral KE ST in older adults, aged 50-
85 yr., to determine the changes in absolute and relative PP with ST.  Subjects (N = 
114) were genotyped for the IGF1 CA repeat polymorphism and grouped as 
homozygous for the 192 allele, heterozygous, or non-carriers of the 192 allele. 
However, sample sizes varied substantially among the various dependent variables. 
Differences in baseline PP and changes with ST among genotype groups were 
determined using ANCOVA (covariates include: age, sex, baseline fat-free mass). 
Results: The 192 homozygotes had significantly lower baseline PP at 50%, 60%, and 
70% of 1-RM strength than the non-carriers when age, sex and baseline fat-free mass 
was covaried. This same relationship was observed when the highest PP within these 
  
ranges was compared. Both absolute and relative PP increased significantly with ST 
in all genotype groups as expected, but there were no significant relationships 
between IGF1 genotype and any of the PP changes. Conclusion: Despite a 
significant relationship between IGF1 genotype and knee extensor peak power at 
baseline, IGF1 genotype does not appear to influence changes in knee extension peak 
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     Sarcopenia is the loss of muscle mass with age and is associated with declines in 
muscle strength (62) muscle power (220,148,179) and losses of functional abilities 
(228,296).  Muscle power, the product of force generation and the velocity of muscle 
contraction, is a particularly important component of sarcopenia because its age-
related deterioration rate is greater than losses in muscle strength or muscle mass 
(148,179,260) and it is believed to be more closely associated with declines in 
functional abilities than muscle strength in elderly population (171,217).  For 
example, leg power explains a larger portion of the variation within physical function 
performance than does leg strength in older men and women (22,119).  
       Several types of interventions have been proposed for the prevention and delay of 
the adverse consequences of sarcopenia, but the combined efficacy and safety 
qualities of strength training (ST) make it the intervention of choice for older adults 
(122,238,121).  ST increases muscle power in older adults even when moderate-
velocity protocols are used (134,261,75).  However, muscle response to ST is highly 
variable, even among those with similar physical characteristics undergoing 
equivalent training programs (58,126,125,33). 
       These large inter-individual differences, along with the high heritability values 
for muscle power (273,35), suggests that genetic factors may be influential.  Also, 
power is influenced by both maximal force production (strength) and muscle mass, 
both of which are highly heritable phenotypes (123).  In addition, the adaptation in 




Despite the importance of muscle power as a major component of sarcopenia, little 
information is available on the influence of specific gene polymorphisms on muscle 
power at baseline or  in response to ST in older adults (59). 
        The contribution of insulin-like growth factor I (IGF-I) in the modulation of 
muscle mass and function across the entire life span has been well established 
(86,27,192).  Circulating levels of IGF-I decline with age, and is related to sarcopenia 
(95,279).  Low plasma IGF-I levels are associated with slow walking speed and self-
reported difficulty in mobility tasks, suggesting a role of IGF-I in disability and frailty 
in the elderly (37).  The expression of IGF-I within individual muscle fibers is 
correlated with muscle hypertrophy resulting from mechanical overload (212,308). 
Moreover, over expression of IGF-I in skeletal muscle elicits muscle fiber 
hypertrophy (47,192) and IGF-I mRNA levels are associated with muscle 
hypertrophy (307,49).  Some recent studies in transgenic mice have also related the 
over expression of IGF-I in skeletal muscle to prevention of age-related decreases in 
intracellular calcium and specific force in a muscle (89,298).  In addition, IGF-I is a 
potent trophic factor for motor neurons (40) and over expression of IGF-I in skeletal 
muscle prevents denervation of fast muscle fibers in aged mice (178).  Though only 
few studies have investigated the association between IGF-I and muscle power in 
humans, the findings of one such study indicated that in healthy elderly women, 
lower values for quadriceps muscle power and optimal shortening velocity are related 
to lower circulating levels of IGF-I (149).  In another study, IGF-I was a significant 
predictor of muscle power in older adults, even after adjusting for potential 




have shown ST to be effective in increasing muscle IGF-I mRNA and protein levels, 
even in the elderly (101,258) , we are unaware of any studies showing these increases 
are associated with muscle power adaptations with ST.  
        Although numerous factors can influence blood or tissue levels of IGF-I, a large 
percentage of the variability appears to have a genetic basis (116,107).  Studies have 
implicated an area near the IGF1 gene locus with influencing baseline fat free mass 
(FFM) and FFM changes with training, thus making it a strong candidate gene for 
muscle phenotypes (42,267).  A cytosine-adenine (CA)19 dinucleotide repeat 
polymorphism (192 repeat allele) in the promoter  region of the insulin-like growth 
factor 1 (IGF1) gene is associated with blood levels of the IGF-I protein 
(229,183,288,236).  Several studies have also associated this repeat polymorphism 
with functional properties and phenotypes linked to IGF-I protein 
(289,288,236,246,231,286).  Two recent studies have reported that the development 
of muscular strength in response to a ST program is influenced by this IGF1 
dinucleotide repeat polymorphism located in the promoter region (104,147).  The 
exact functionality of this polymorphism is not known, however, the results of the 
above studies suggest that the polymorphism may serve at least as a candidate marker 
for muscle phenotypes associated with IGF-I.  Presently, there are no studies that 
have investigated the relationship between this repeat polymorphism in the IGF1 
gene and muscle power.  Knowledge of this relationship may have important 
implications for understanding the impact of genetics on muscle power.   
       Therefore, the purpose of the study is to determine whether IGF1 genotype in the 




to ST in older adults.  Because of the associations described above between the repeat 
polymorphism in the IGF1 gene and expression of IGF-I protein in muscle and 
between IGF-I protein and skeletal muscle properties, we hypothesize that the repeat 
polymorphism in the IGF1 gene is related to skeletal muscle power at baseline and in 
response to ST.  Due to the substantial loss in muscle power with advancing age and 
the close association between muscle power and performance of functional abilities in 









     One hundred and fourteen relatively healthy, sedentary, predominantly Caucasian 
and African-American men and women volunteers between the ages of 50 and 85 
were recruited in this study. The data for some of these subjects have been previously 
used by two other studies from our group that have explored the relationship between 
IGF1 genotype and strength training response of other muscle phenotypes (147,104).  
All subjects underwent a phone-screening interview, received medical clearance from 
their primary care physician and completed a detailed medical history prior to 
participating in this study.  All subjects were nonsmokers, free of significant 
cardiovascular, metabolic, or musculoskeletal disorders that would affect their ability 
to safely perform heavy resistance exercise.  Subjects who were already taking 
medications for at least three weeks prior to the start of the study were permitted into 
the study as long as they did not change medications or dosages at any time 
throughout the study.  After all methods and procedures were explained, subjects read 
and signed a written consent form, approved by the Institutional Review Board of the 
University of Maryland, College Park.  All subjects were continually reminded 
throughout the study not to alter their regular physical activity levels or dietary habits 
for the duration of the investigation, and body weight were measured weekly 
throughout the study to help confirm compliance to maintaining a stable diet.  All 







     This retrospective gene association study with a longitudinal ST intervention 
utilized a pre and post non random design.  The IGF1 genotype groups serve as the 
independent variable, whereas KE PP assessed at baseline and the change in KE PP 
with ST serves as the dependent variables to test the hypotheses. 
Genotyping 
Blood was drawn from the antecubital vein of the dominant arm, after at least twelve 
hours of fasting. Genomic DNA was extracted from peripheral lymphocytes.  The CA 
microsatellite of IGF1 was amplified using polymerase chain reaction (PCR) using 
fluorescence tagged primers.  Previously published PCR primers flanking the CA 
polymorphism were used (236).The ABI 3100 DNA sequencer (PE Applied 
Biosystems) and AB Genescan/Genotyper 2.5 software program (PE Applied 
Biosystems) were used to determine the genotype of the CA repeat microsatellite in 
the promoter region of the IGF1 gene.  Genotype assignment was based on the 
method described by Rosen et al (236) (e.g., 19 CA repeats = 192 bp), in which these 
authors found the 192 allele to be the most common and thus compared it with the 
other alleles for this microsatellite (236).  Direct sequencing was used to confirm the 
accuracy of all genotyping methods. 
 Body Composition Assessment  
     Body composition was determined by dual-energy x-ray absorptiometry (DXA) 
using the fan-beam technology (model QDR 4500A, Hologic, Waltham, MA).  A 
total body scan was performed at baseline and again after the ST program using 




FFM, fat mass, and % fat were analyzed using Hologic version 8.21 software for 
tissue area assessment.  Total body FFM was defined as lean soft tissue mass plus 
total body bone mineral content (BMC).  The coefficients of variation (CV) for all 
DXA measures of body composition were calculated from repeated scans of 10 
subjects who were scanned three consecutive times with repositioning. The scanner 
was calibrated daily against a spine calibration block and step phantom block 
supplied by the manufacturer.  In addition, a whole body phantom was scanned 
weekly to assess machine drift over time. 
Body weight was measured to the nearest 0.01 kg with subjects dressed in 
medical scrubs, and height was measured to the nearest 0.1 cm using a stadiometer 
(Harpenden, Holtain, Wales, UK).  Body mass index (BMI) was calculated as weight 
(kg) divided by height (m) squared.  
Muscular Strength  
     One-repetition maximum (1- RM) strength test.  The 1-RM strength test was 
performed for both legs on a  knee extension (KE) exercise at baseline and after 10-
week of unilateral (one-legged) KE ST program, using an air-powered resistance 
machine (Keiser A-300 Leg Extension machine, Keiser Sports/Health Equip. Co., 
Inc., Fresno, CA).  This exercise was chosen because it can be easily tested in a 
standardized way using objective criteria.  Before the regular ST program, 1- RM 
testing, and power testing were performed, subjects underwent at least two 
familiarization sessions in which the participants completed the training program 
exercises with little or no resistance and were instructed on proper warm-up, 




conducted in order to familiarize the subjects with the equipment, to help control for 
the large 1- RM strength gains that commonly result from skill (motor learning) 
acquisition during the initial stages of training, and to help prevent injuries and reduce 
muscle soreness following the strength testing protocol.  When appropriate, straps 
and/or belts were used to stabilize the subject so that recruitment of outside muscle 
groups was minimized.  Arms were placed either across their chest or on thighs 
during exercise, but positioning was consistent from pre- to post testing within 
subjects.  The 1- RM was achieved by gradually increasing the resistance from an 
estimated sub-maximal load after each successful exercise repetition until the 
maximal load was obtained.  A light system was used to indicate a successful attempt 
when the knee was extended to the full ROM. Approximately the same number of 
trials (6-8) and the same rest periods between trials (~ 1 min) were used to reach the 
1- RM after training as before training.  Subjects rating of perceived exertion and 
pain/discomfort were monitored and recorded throughout the test.  The same 
investigator conducted strength tests for each subject both before and after training 
and standardized procedures with consistency of seat adjustment, body position, and 
level of vocal encouragement were used. 
Muscle Volume 
     Computed Tomography (CT).  To quantify quadriceps muscle volume (MV), CT 
imaging of the trained and untrained thighs was performed (GE Lightspeed Qxi, 
General Electric, Milwaukee) at baseline and during the last weeks of the 10-week 
unilateral ST program.  Axial sections of both thighs were obtained starting at the 




patella while subjects were in a supine position.  Section thickness was fixed at 10 
mm, with 40 mm separating each section, based on previous work in our laboratory 
by Tracy et al (281).  Quadriceps MV was estimated based on using a 4 cm interval 
between the center of each section.  Each CT image was obtained at 120 kVp with the 
scanning time set of 1 s at 40 mA. A 48-cm field of view and a 512 X 512 matrix was 
used to obtain a pixel resolution of 0.94 mm.  Two technicians analyzed images for 
each subject using Medical Image Processing, Analysis, and Visualization (MIPAV) 
software (NIH, Bethesda).  Briefly, for each axial section, the cross-sectional area 
(CSA) of the quadriceps muscle group was manually outlined as a region of interest. 
The quadriceps CSA was manually outlined in every 10 mm axial image from the 
first section closest to the superior border of the patella to a point where the 
quadriceps muscle group was no longer reliably distinguishable from the adductor 
and hip flexor groups.  The same number of sections proximal from the patella was 
measured for a particular subject before and after training, to ensure within subject 
measurement replication.  Investigators were blinded to subject identification, date of 
scan, and training status, for both baseline and after training analysis.  Repeated 
measurement CV was calculated for each investigator based on repeated measures of 
selected axial sections of one subject on two separate days.  Final MV was calculated 
using the truncated cone formula as reported by Tracy et al (281) and described by 
Ross et al (237). 
 Peak Muscle Power 
       Determination of KE PP was performed on a customized Keiser pneumatic 




Fresno, CA), specifically designed for muscle power assessment.  The K410 machine 
is equipped with load cell force transducers and position sensors to detect rotary 
motion at the joint.  Additionally, a computer program (A430 version 1.6.0.19 (2003), 
Keiser Sports/Health Equip. Co., Inc., Fresno, CA) was used to measure muscle 
power in Watts.  The Keiser machine measures maximal movement velocity and 
force production to calculate muscle power in watts, using a specialized timing device 
and load cell. 
Prior to testing, seated blood pressure was measured after five minutes of rest, 
and then a one-minute warm-up was performed on a stationary cycle ergometer. 
Subjects were then positioned on the K410 with the medial condyle aligned with the 
axis of rotation of the machine arm.  Subjects were instructed to cross their arms 
across their chest, and a seat belt attached to the machine was securely fastened 
around the waist to help isolate the knee extensor muscle group.  Subjects were 
instructed to perform a knee extension with each leg unilaterally at a resistance of ~ 
30% of their measured 1- RM and at ~ 50% of their maximal velocity, as a warm-up 
trial.  Following a 30 s rest period, subjects performed three power tests on each leg 
alternating between right and left at 50%, 60%, and 70% of their 1- RM, with a 30 s 
rest period between each of the three trials and 2 min rest periods between each 
increase in resistance.  The tester offered standardized oral encouragement to each 
subject to extend his or her knee as quickly and forcefully as possible during each 
trial.  The highest peak power value of the three trials for each % of 1- RM was 
selected.  The entire procedure was repeated 48-72 h later and the higher of the two 




power.  This test was repeated during the last week of the 10-week unilateral ST 
program for the post training test.  During this latter test, an attempt was made to find 
a load that could be replicated from baseline testing that represented 50% or 60% of 
the post training 1- RM for testing at the same absolute load.  When a replicable load 
was not found that fell at one of these relative loads (i.e., 50% or 60% of the post 
training 1- RM), the load that was used at 50% of the baseline 1- RM value was used 
for the post training same absolute load (regardless of the % of post training 1- RM 
that the load represents) during the post training test.  The power machine was 
calibrated daily against a standardized weight supplied by the manufacturer.  Muscle 
power testing was shown to be both reliable and valid in a previous study using 
similar equipment, with an intra-class correlation coefficient of 0.91 (34). 
Training Program 
     The training program consisted of unilateral (one-legged) training of the knee 
extensors of the right leg, three times per week, for ~ 10 weeks.  Training was 
performed on a Keiser A-300 air powered leg extension machine.  This machine 
allows for ease of changing the resistance without interrupting the cadence of the 
exercise.  The untrained control leg was kept in a relaxed position throughout the 
training program. Subjects performed a warm-up on a bicycle ergometer for 
approximately two minutes prior to each training session.  Following the two 
familiarization training sessions previously described, the training consisted of five 
sets of knee extension exercise for those < 75 yrs of age and four sets for those ≥ 75 
yrs of age.  We did not have those ≥ 75 perform the last set because of our concern 




overtraining, which has been shown to result in a reduction in strength gains with 
training (207).  The first set was considered warm-up and consisted of five repetitions 
at 50% of the 1- RM strength value.  The second set consisted of five repetitions at 
the current 5 -RM value, which was initially estimated based on our previous data 
showing that it corresponds to ~ 85% of 1- RM in most people.  Adjustments were 
made as needed during each training session so that the resistance used resulted in 
failure to complete a 6
th
 repetition.  The 5 -RM value was increased continually 
throughout the training program to reflect increases in strength levels.  The first four 
or five repetitions of the third set were performed at the current 5- RM value, then the 
resistance was lowered just enough to complete one or two more repetitions before 
reaching muscular fatigue.  This process was repeated until a total of 10 repetitions 
were completed.  This same procedure was used in the fourth and fifth sets, but the 
total number of repetitions was increased in each set to 15 and 20 reps, respectively. 
This procedure allowed subjects to use near maximal effort on every repetition while 
maintaining a relatively high training volume.  The second, third, fourth, and fifth sets 
were preceded by rest periods lasting 30, 90, 150, and 180 seconds, respectively.  A 
red light indicator was visible to the participant and flashed only when the full ROM 
was reached.  The shortening phase of the exercise (often called concentric phase) 
was performed in approximately two seconds, and the lengthening phase (often called 
eccentric phase) lasted approximately three seconds.  A seat belt was worn 
throughout the exercise session and subjects placed their arms across their chest 
during exercise in order to minimize involvement of assisting muscles.  Subjects 




training session. Trained research assistants carefully monitored the work-outs of 
each participant for every training session during the ~10 weeks of training. They 
adjusted the resistance accordingly within the set and for the following training 
session in order to ensure each repetition was performed using the proper resistance 
and form through the full ROM. 
Statistical Analysis 
      All statistical analyses as described below were performed using SAS software 
(SAS version 9.1, SAS institute, Inc., Cary NC).  The significance of the statistical 
model was set at P < 0.05 and data comparisons are expressed as means +/- SE. 
To examine the effect of the promoter genotype on skeletal muscle power at baseline 
and in response to ST, an analysis of covariance was used for each dependent variable 
to test for differences among means.  The three levels of the predefined groupings of 
genotype at the IGF1 promoter locus were defined as the fixed effect.  To reduce 
error variance and increase precision, age, gender and baseline FFM were used as 
covariates for the analysis.  Race and usage of ACE inhibitors, diuretics, anti-
inflammatory medications, and  hormone replacement therapy (HRT) did not reach 
significance as covariates and were therefore not included  in the final model.  To 
determine whether the data for the Caucasian and African-American populations 
could be pooled for the potential influence of race on  the IGF1 genotype and  muscle 
power relationship at baseline and in response to ST, analysis was done with and 
without including race as a covariate and no differences in results were observed.  For 
this reason, data from both race groups was combined for all other genotype analyses 




To explain percent variability explained by genotype, the proportion of the 
variance explained by the 192 CA dinucleotide repeat polymorphism , the R
2
 of the 
full model with IGF1 genotype and all covariates was compared to that of the 
constrained model without IGF1 genotype in the model. 
Statistical Power.  Post-hoc power analysis was done to determine the power level 
given the pre-set sample size using all data from the present study, with α. Set at 0.05. 
Statistical power was ≥ 0.8 for all baseline muscle power comparisons between the 
192 homozygotes and non-carriers of the 192 allele. The statistical power to detect 
baseline muscle power differences between 192 homozygotes and 192 heterozygotes; 
192 heterozygotes and non-carriers of the 192 allele was < 0.5 and < 0.25 for changes 
in muscle power with ST.  Based on this analysis, a sample size of >500 would be 
required to achieve a statistical power of 0.8 to detect differences among genotype 
groups for changes in muscle power with ST. This value would increase substantially 
if attrition and ethnicity were considered. 







     Subject characteristics and muscle properties at baseline and after ST for men (n = 
52) and women (n = 62) are shown in Table 1.  Strength increased significantly in the 
trained leg in men (~ 25.9 %) and in women (~29.3 %, both P < 0.001) with ST, 
irrespective of IGF1 genotype.  These increases are likely reduced by our 
familiarization procedures performed prior to baseline strength testing and designed 
to control for motor learning effects (see methods for explanation).  Muscle volume 
(MV) also significantly increased in both men (~ 8.8 %) and women (~ 8.1 %; both P 
< 0.001).  There were no significant changes in BMI, body mass , %  body fat, or 
FFM in either men or women with ST.  Table 2 reveals no significant differences in 
age, height, body mass, BMI, , % body fat or FFM at baseline or in response to 
training among the three IGF1 promoter genotype groups. 
     As shown in Table 3, there was a significant increase (31 ±  6 W; 9 %; P < 0.001) 
in knee extensor  absolute PP (i.e., PP at the same absolute resistance at both baseline 
and after ST) in all subjects with ST, irrespective of IGF1 genotype.  Relative PP 
(i.e., PP at 50%, 60% and 70% of baseline 1- RM and 50%, 60% and 70% of the 
improved 1- RM after ST) also significantly increased (20 ± 5; 6 %; P < 0.001, 15 ± 
6; 4 %; P < 0.05, & 13 ± 6; 4 %; P < 0.05, respectively) in all subjects, irrespective of 
genotype. Finally, in all genotype groups, the overall highest relative peak power, 
irrespective of the % of 1- RM,  also showed a significant increase ( 22 ± 4; 6%;  P < 
0.001).  In the current sample population, the overall highest relative peak power for 




value.  The only variables that changed significantly in the untrained leg in all 
subjects was 1- RM strength (P < 0.001) and this was likely due to the cross-
education effect.  The changes in 1- RM, muscle volume, absolute PP and relative PP 
in the trained leg were significantly different than those  of  the untrained leg in all 
subjects ( all at least  P < 0.05). 
     Genotype results. Due to the longitudnal design of the investigation and multiple 
variables examined within each genotype group, many  of the measures have  missing 
data points.  The minimum number of subjects for any of the main variables with ST 
is 18, 24 and 15  for the 192   homozygotes, 192 heterozygotes, and all other 
genotype groups, respectively.  As shown in table 4, genotype distributions for the 
IGF1 genotype groups were 36 (32%), 55 (48%), and 23 (20%) for the 192 
homozygotes, 192 heterozygotes and “all other genotypes” group, respectively, and 
were comparable to those reported previously (236,288).  The 192 allele was 
however, observed more frequently  in the Caucasians than African-Americans, who 
had  a higher frequency of the non-192 allele, as reported  previously  (140,246).  
    Table 5a shows the baseline differences in peak power in all subjects by IGF1 
genotype.  The 192 homozygotes had significantly lower baseline PP at 50%, 60%, 
and 70% of 1 RM strength  ( 58 W, 64 W, & 58 W, respectively) than the non-
carriers (P < 0.05) when age, sex and baseline FFM were covaried.  This same 
relationship was observed when the highest PP within these ranges was compared. 
Partial R
2
 analysis indicated that the IGF-1 genotype explained 2.0% - 2.3% of the 
variance in baseline PP.  As sex was a significant covariate in the model for the 




baseline peak power values of each sex group by IGF1genotype.  Table 5b and Table 
5c show the differences in baseline PP in women and men respectively by IGF1 
genotype.  As shown  in Table 5b,   the 192 homozygote women had significantly 
lower baseline PP at 50% and 70% of 1 RM strength (60 W & 59 W respectively) 
than the non-carriers (P < 0.05) when age and baseline FFM were covaried. In 
women, the overall highest relative PP was also significantly lower in 192 
homozygotes and 192 heterozygotes by 69 W & 52 W, respectively, than the non-
carriers (P < 0.05).  There were no baseline differences in peak power by IGF1 
genotype in men as shown in Table 5c .   
      Table 6 shows the differences in change in peak power with ST by IGF1 genotype 
in all subjects.  The change score is calculated as the difference between the muscle 
power change with training in the trained leg and that of  the control leg during this 
same time period.  Absolute and relative peak power change scores did not differ 
significantly among the IGF1 promoter genotype groups ( P > 0.05), when covarying 
for age, sex and baseline FFM. 
      As shown in Tables 7a, 7b, 7c and 7d, an exploratory sub-analysis revealed some 
race specific differences in IGF1 genotype influence on both baseline and change in 
peak power  with ST, when covarying for age, sex and baseline FFM.  No significant  
differences were observed in baseline or change in peak power  with ST among the 
IGF1 genotype groups in Caucasians, whereas, African-American 192 homozygotes 
had significantly lower PP than non-carriers at baseline 70% of 1-RM and at  the 
overall highest relative baseline PP ( both P < 0.05).  The African-American 192 




both baseline and after ST) and relative peak power (60% of 1-RM at baseline and 



















     To our knowledge, this is the first study to examine the influence of IGF1 
genotype on skeletal muscle power at baseline and in response to ST in older adults. 
Although the results support our hypothesis that IGF1 genotype influences knee 
extensor PP at baseline, it appears to only account for a small portion of the variation 
in muscle power (~ 2%).  Contrary to our expectations, the data do not support our 
hypothesis of a significant influence of IGF1 genotype on change in knee extensor PP 
with ST. This latter finding, however, does not completely rule out IGF1 as an 
important gene or the IGF1 (CA)19  repeat polymorphism as an important gene locus 
for influencing muscle power response to ST.  Nevertheless, it does appear that other 
gene loci should be explored in future investigations to better determine the role of 
gene polymorphisms in explaining variability in muscle power response to ST.   
        The common IGF1 (CA)19  microsatellite polymorphism  may alter transcription 
through its regulatory elements (175,301), and has been associated with decreased 
circulating levels of the IGF-I protein in some (80,236,229) but not all studies 
(4,56,132).  This polymorphism is also associated with functional properties and 
phenotypes linked to the IGF-I protein (236,231,246,286,288,289).  Despite the 
known effects of IGF-I on muscle biology, we could only find two reports that have 
examined this polymorphism in relation to skeletal muscle phenotypes.  Both of these 
studies reported no significant differences in baseline muscle strength, muscle volume 
or muscle quality (MQ) among IGF1 CA repeat genotype groups (147,104).  
However, Kostek et al (147) found a significant influence of the IGF1 genotype on 




by Hand et al (104) who observed  a significant  IGF1 main effect, as well as a 
significant gene by gene interaction effect  for  IGF1 and  calcineurin B (PPP3R1)  
for change in strength and MQ with ST.  The results of the present study add to these 
two studies, which used some of the same subjects who were used in this 
investigation, by showing a significant association of this IGF1 polymorphism with 
baseline knee extensor PP, but not with change in knee extensor PP with ST.  Until 
corroborative findings from independent cohorts support our baseline findings, it may 
be premature to speculate on potential mechanism.  Nevertheless,  one possibility for 
explaining such a link might relate to the trophic effects of IGF-I on neuronal and 
muscular tissues, given that muscle power is associated with both muscular and 
neurological factors (111).  
     Our results show that the non-carriers of the 192 allele had the highest PP values, 
followed by the 192 heterozygotes and 192 homozygotes, respectively, but only the 
women were significantly higher.  Our finding of a sex-specific association between 
IGF1 genotype and knee extensor PP is similar to that reported by Kostka et al (149), 
who showed a positive  correlation between plasma IGF-I levels and quadriceps 
power in women, whereas, no such correlation was observed in men.  They 
speculated that cortisol and testosterone levels may be better predictors of muscle 
function in men than IGF-I levels.  While it is possible that the physiologically low 
concentration of testosterone in women may induce compensatory stimulation of the 
growth hormone/IGF-I axis in response to an increase in muscle loading, it is far 
beyond the scope of this study to determine potential mechanisms for this sex-specific 




IGF1 genotype on muscle power warrants further exploration.  Given that elderly 
women have 20-80% lower muscle power than men (260,16,64), which predisposes 
them to a greater and earlier risk of falls and loss of independence than men 
(268,201), muscle power is an important issue for health status and functional 
abilities in older women.  Moreover, the relative power assessed may have additional 
implications.  For example, Cuoco et al. (48) demonstrated that lower extremity 
power at 40% of 1 RM explained a greater proportion of the variance in habitual gait 
velocity than did muscle power at 70% of 1 RM.  In this context, we found a 
significant association between IGF1 genotype and PP at a lower relative intensity 
(50% of 1 RM).  The positive association between IGF1genotype and PP at higher 
relative intensities (e.g., 70% of 1 RM), may also have important functional 
implications for other activities of daily living, such as getting in and out of a chair, 
which  require a higher percentage of maximal force production (303,306). 
     Although there was a significant association between IGF1 genotype and baseline 
knee extensor power, no such association was observed with knee extensor power 
gain after training.  This is in contrast to the positive associations reported in previous 
studies between IGF1 genotype and muscle strength response to ST  (147,104).  
Based on the principle of specificity, it is not surprising that we observed a greater 
increase in 1-RM strength than power, given our moderate velocity, heavy resistance 
training protocol.  However, it is conceivable that this could at least partially explain 
the significant associated influence of IGF1 genotype on strength response to ST 
previously reported. The more subtle changes in power compared to strength may 




than strength, even if a true relationship existed.  In addition due to the longitudinal 
design of the investigation, the small sample size for change in muscle power in each 
genotype group resulted in low statistical power and a high possibility of type 2 error.  
Thus, the inconclusive results in influence of IGF1 genotype on muscle power 
response to ST may be due to lack of statistical power and future studies with large 
sample size should confirm this finding. 
     Previous studies have reported significant differences in  strength, muscle volume 
and lower extremity performance among  racial/ethnic groups (222,64,197,296). 
Although a complete explanation for these differences has not been identified it is 
conceivable that racial heterogeneity in circulating IGF-I levels could offer at least a 
partial explanation.  Racial differences in IGF-I levels  is associated with  risk of 
diabetes, cardiovascular disease, and cancer in certain race groups (250,23).  
Although the findings of racial differences for the influence of IGF1 genotype on 
muscle phenotypes in the current study are based on insufficient sample sizes, they 
may offer support to the need for future studies to further explore the role of the IGF-I 
axis in explaining racial/ethnic differences in muscle phenotypes.   In this context, it 
is possible that racial/ethnic differences in serum IGF-I could occur because of 
genetic differences in IGF-I regulation among different race/ethnic groups, as a large 
percentage of variability in serum IGF-I levels has a genetic basis (107,116).  This is 
further supported by our own data and the reports of previous investigations showing 
an ethnic variation in the frequency of the 192 allele (56,140), which has been 
associated with serum IGF-I levels.  To address the issue of racial influences on the 




baseline or in response to exercise training,  future studies will need to use large 
sample size with similar  numbers of subjects from different racial and genotype 
groups, controlling for the possible divergent effects this polymorphism might have 
among  different racial/ethnic  backgrounds (118).  
      The use of the untrained leg adds a unique design that controls  for  drift in values 
due to common variations in methodology, biology, season of the year, genetic 
differences between groups, or differences in attention between experimental and 
control groups.  This in combination with our data showing no cross-education effect 
of muscle power in the untrained leg with ST of the trained leg minimizes the level of 
variance due to experimental error and better isolates the independent effects of ST 
and influences of gene variations.  Furthermore, our measure of PP as the highest 
power value attained during a single trial, unlike previous investigations  reporting PP 
as the highest average power obtained during multiple trials of a power test 
(66,76,134,127), might be a more accurate measure of the explosive capacity of the 
trained musculature.  Additionally, our measure of PP  might be more functionally 
relevant to events such as catching oneself from a fall or quickly correcting a loss of 
balance, because these actions would likely be limited by the ability to 
instantaneously maximize both  strength and speed of movement (91,304).  More 
specifically, since knee weakness is strongly correlated to the occurrences of falls and 
disability in the elderly (96), quadriceps power measured in the current study may be 
considered one of the most important determinants of functional independence in 




     Despite the value of our design for the internal validity of the study, there are 
several limitations in the current investigation.  Although the untrained leg helps 
minimize the error variance in the dependent variables of interest, the small sample 
size in each of the genotype groups and the lack of an independent cohort for 
comparison still poses a major limitation for genotype association studies.  Another 
limitation is our moderate velocity training protocol (~ 2 seconds during the 
shortening phase and (~ 3 seconds during the lengthening phase).  A faster velocity 
training program would  likely  optimize  gains in power (76).  We chose this  ST 
protocol for its  safety and effectiveness  for  improving  muscle mass, strength, and 
muscle quality, as well as power (58,126,280,157),  all key components of 
sarcopenia.  The relatively large age range of subjects (50-85 yrs) is also a limitation. 
It is possible that the youngest subjects in the study may have slightly different 
training responses than the older ones.  We attempted to control for this statistically 
by covarying for age, but an experimental control of narrowing the age range would 
have likely provided a better control for this.  Moreover, the exact functional role for 
this IGF1 polymorphism cannot be determined from this study.  It is possible that the 
length of the polymorphism could be affecting expression levels or that this 
polymorphism is in linkage disequilibrium with a functional polymorphism that 
affects phenotypes related to IGF1 expression.  As recommended in previous studies, 
to address the functionality of this polymorphism in-vivo in humans, IGF1 muscle 
expression data and IGF-I cellular mediators though muscle biopsy samples would be 
needed along with a method of grouping that could account for heterozygotes who 




cell culture system could be used to address this in-vitro.  Finally, this investigation 
shows the relationship between only one polymorphism in only one gene at only one 
locus. However, muscle power is a complex phenotype, which is probably influenced 
by multiple genetic pathways and environmental influences.  Performing this type of 
study, however, would require an extremely large sample size, likely to require 
multiple training cites.   
     Therefore, any future studies that address the question of genetic influences on 
muscle power response to ST will not only need to accommodate the limitations of 
this current study, but will also need to consider PP assessments in other movements 
experienced in common activities of daily living by older adults, such as upper leg 
extension used in the leg press exercise.  Future studies could provide more 
information on the functionality of IGF1 and other gene polymorphisms by 
measuring mRNA and/or protein levels of IGF-I in muscle samples.  It may also be 
useful to study this and other IGF pathway gene polymorphisms as they relate to 
contraction velocity to get useful insights into potential mechanisms for genetic 
predispositions for decline in muscle power and function.  This recommendation is 
based on the fact that deficits in movement velocity have been reported as the primary 
cause of age-related power losses, especially in older women (41,55) and have 
significant correlations with functional performance measures such as 6-m walking 
speed and chair and stair-climb time (46).  Studies analyzing the association between 
this polymorphism and functional abilities in elderly populations would also be useful 
to make any recommendations for genetic susceptibility to sarcopenia based on this 




needed and should be conducted in various ethnic backgrounds to explain a greater 
proportion of the variance of these complex phenotypes.  
     In summary, the present study is the first to demonstrate a significant association 
between IGF1 genotype and muscle power in older adults.  When confirmed and 
combined with those from larger cohorts, possibly targeting other sites, the results 
from this study could help contribute to a better understanding of the role of genetics 
in decline in muscle power with aging.  This information could then eventually help 
to develop better screening procedures for the prevention and treatment of sarcopenia.  
However, the application of this information to this level of practical use will have to 


















Table 1. Physical characteristics at baseline and after strength training (ST) in men and women.     
         
           Men n= 52
1
  Women n=62
2
 
         
  Baseline  After ST  Baseline  After ST 
Age (yr)  65 (8)        _ _  65 (9)          _ _ 
 
Height (cm) 174 (6.6)        _ _  162 (6.2)          _ _ 
 




) 28.1 (3.6)  28.2 (3.6)  28.2 (5.7)  28.2 (5.9) 
 
Body Fat (%) 27.7 ( 5.1)  27.6 (4.7)  39.1 (6.1)  38.8 (6.0) 
 
Fat-Free Mass (kg) 61.3 (7.6)  61.6 (7.3)  44.0 (5.6)  44.2 (5.9) 
 




)  1759 (276) 1914 (313)* 1153 (228) 1247 (232)* 
                  
Values are means (SD). Data presented are for all subjects with baseline and after ST measurements. 
BMI = body mass index; 1-RM = knee extension one-repetition maximum; kg = kilograms. 
1
There were 49 subjects for weight, BMI, FFM & body fat %, 51 for muscle volume, 52 for 1-RM  
  that had both baseline and after ST values.      
2
There were 60 subjects for body fat %, 61 for muscle volume & FFM, 62 for weight, BMI & 1-RM   
  that had both baseline and after ST values. 
3
Muscle volume of the knee extensors.              
*Significantly different than baseline (P < 0.001).      




Table 2. Physical characteristics for all subjects by IGFI genotype               
  192  Homozygotes  192 Heterozygotes  All other Genotypes  
  Baseline   After ST  Baseline  After ST  Baseline  After ST  
Age (yr)  63 ± 1 (36) _ _  66 ± 1 (55) _ _  64 ± 2 (23) _ _  
 
Height (cm) 168.3 ± 1.5 (36)  _ _  165.9 ± 1.2 (55) _ _  169.9 ± 1.8 (23) _ _  
 




) 28.0 ± 1.0 (35) 28.0 ± 1.0 (35) 28.5 ± 1.0 (53) 28.6 ± 1.0 (53) 27.5 ± 1.0 (23) 27.5 ± 1.0 (23) 
 
Body Fat (%) 34.3 ± 1.4 (35) 34.1 ± 1.3 (35) 34.5 ± 1.1 (53) 34.3 ± 1.1 (53) 32.3 ± 1.8 (21) 31.7 ± 1.7 (21) 
 
Fat-Free Mass (kg) 51.8 ± 1.8 (35) 51.8 ± 1.9 (35) 51.2 ± 1.5 (53) 51.5 ± 1.5 (53) 52.8 ± 2.3 (22) 53.4 ± 2.3 (22) 
 
Male/Female, n 16/20  _ _  25/31  _ _   11/12  _ _  
                            
Values are means ± SEM (n).            
BMI = body mass index; kg = kilograms.           
None of the after-training values were significantly different from baseline (P > 0.05).      
There was no significant differences in age, height, body mass, BMI, body fat %, or FFM at baseline or in response to training among the three 










Table 3. Changes in 1- RM knee extensor strength, muscle volume, peak power with strength training (ST) in the trained and untrained leg in 
all subjects (n = 62-114)
¶
 
     Trained leg  Untrained leg    
1 RM (kg)       6.6 ± 0.3
bc









)     122 ± 6
bc
     -2 ± 4  
 
   
Relative Peak Power at 50% of 1-RM  (W)    20 ± 5
bc
     -7 ± 4  
 
   
Relative Peak Power at 60% of 1-RM
 
 (W)    15 ± 6
ad
     -5 ± 4  
 
   
Relative Peak Power at 70% of 1-RM (W)    13 ± 6
ad
     -7 ± 4  
 
   
Relative Overall  highest Peak Power (W)   22 ± 4
bc
     -3 ± 3  
 
   
Absolute Peak Power (W)        31 ± 6
bc
         4 ± 3   
 
      
Values are means ± SEM; W = watts; kg =kilograms           
1
Muscle volume of the knee extensors.            
a
Significantly greater than baseline (P <0.05).           
b
Significantly greater than baseline (P <0.001).           
c
Significantly different than the untrained leg (P <0.001).          
d
Significantly different than the untrained leg (P <0.05). 
¶Sample size variability was due to missing data points 



















Table 4. IGF1 CA genotype frequency for all subjects.     
Genotype  
Total 





        
192/192  36 (32)  31 (36)  5 (18)  
        
192/-  55 (48)  42 (49)  13 (46)  
        
Non-carriers 23 (20)  13 (15)  10 (36)  
of the 192       
Allele               
CA = cytosine adenine      













Table 5a. Baseline differences in peak power in the trained leg by IGF1 genotype in all subjects.         
      192  Homozygotes  192 Heterozygotes  All other Genotypes 
              
Relative Peak Power at 50% of 1 RM (W)   330.5 ± 15.0* (26)    357.1 ± 12.7 (37)  388.7 ± 18.2 (18) 
 
Relative Peak Power at 60% of 1 RM (W)   325.6 ± 16.0* (26)     351.3 ± 13.5 (37)  389.2 ± 19.4 (18) 
 
Relative Peak Power at 70% of 1 RM (W)   295.8 ± 14.6* (32)      326.0 ± 12.3 (45)  351.5 ± 17.6 (22) 
 
Relative Overall highest Peak Power (W)     317.6 ± 13.5* (32)     350.4 ± 11.4 (45)   380.2 ± 16.3 (22) 
 Values are least-square means ± SEM (n) when covarying for age, sex and baseline FFM ; W =  watts.     














Table 5b. Baseline differences in peak power in the trained leg by IGF1 genotype in women.         
      192  Homozygotes  192 Heterozygotes  All other Genotypes 
              
Relative Peak Power at 50% of 1 RM (W)   224.3 ± 14.8* (12)  243.4 ± 11.5   (21)   284.2 ± 18.6 (8) 
 
Relative Peak Power at 60% of 1 RM (W)   223.8 ± 15.8   (12)  235.2 ± 12.3   (21)    283.7 ± 19.9 (8) 
 
Relative Peak Power at 70% of 1 RM (W)   211.0 ± 13.7* (17)  226.4 ± 11.2   (27)   270.1 ± 17.2 (11) 
 
Relative Overall highest Peak Power (W)     224.1 ± 12.7* (17)   241.5 ± 10.4* (27)    293.4 ± 16.0 (11) 
 Values are least-square means ± SEM (n) when covarying for age, sex and baseline FFM ; W = watts.     


















Table 5c. Baseline differences in peak power in the trained leg by IGF1 genotype in men.         
      192  Homozygotes  1   192 Heterozygotes  All other Genotypes 
              
Relative Peak Power at 50% of 1 RM (W)   428.4 ± 24.7 (14)  465.4 ± 22.3 (16)  505.7 ± 29.1 (10) 
 
Relative Peak Power at 60% of 1 RM (W)   421.1 ± 26.0 (14)  460.4 ± 23.5 (16)  508.7 ± 30.6 (10) 
 
Relative Peak Power at 70% of 1 RM (W)   396.6 ± 25.6 (15)  436.9 ± 22.7 (18)  470.6 ± 30.0 (11) 
 
Relative Overall highest Peak Power (W)     428.1 ± 23.4 (15)   473.4 ± 20.7 (18)   505.6 ± 27.5 (11) 
 Values are least-square means ± SEM (n) when covarying for age, sex and baseline FFM ; W = watts.     
There were no significant differences in any of the baseline power values among the three IGF1 promoter genotype groups,     



















Table 6. Change in peak power with ST by IGF1 genotype in all subjects.       
      192  Homozygotes  192 Heterozygotes  All other Genotypes 
              
Absolute Peak Power (W)    12.9 ± 11.6 (20)  27.6 ± 9.6 (30)  18.9 ± 13.4 (15) 
 
Relative Peak Power at 50% of 1 RM (W)   25.6 ± 9.8 (18)  22.8 ± 9.3 (24)  18.2 ± 13.8 (15) 
 
Relative Peak Power at 60% of 1 RM (W)   12.8 ± 9.3 (17)  21.6 ± 10.0 (26)  3.8 ± 12.0 (15) 
 
Relative Peak Power at 70% of 1 RM (W)   9.4 ± 9.8 (24)  22.6 ± 8.4 (33)  0.8 ± 12.4 (15) 
 
Relative Overall highest Peak Power (W)     19.2 ± 9.1 (25)   28.4 ± 7.6 (36)   16.8 ± 10.7 (18) 
 Values are least-square means ± SEM (n) when covarying for age, sex and baseline FFM ; W = watts.     
Absolute and relative peak power change scores did not differ significantly among the IGF1 promoter genotype groups when 



















Table 7a. Baseline differences in peak power in the trained leg by IGF1 genotype in Caucasians.         
      192  Homozygotes  1   192 Heterozygotes  All other Genotypes 
              
Relative Peak Power at 50% of 1 RM (W)   345.0 ± 16.3 (23)  364.3 ± 14.3 (30)  404.5 ± 25.3 (10) 
 
Relative Peak Power at 60% of 1 RM (W)   342.3 ± 17.0 (23)  355.6 ± 14.9 (30)  400.3 ± 26.4 (10) 
 
Relative Peak Power at 70% of 1 RM (W)   305.4 ± 15.1 (28)  326.9 ± 13.0 (37)  346.6 ± 23.6 (12) 
 
Relative Overall highest Peak Power (W)     326.9 ± 14.3 (28)   352.7 ± 12.3 (37)   379.0 ± 22.3 (12) 
 Values are least-square means ± SEM (n) when covarying for age, sex and baseline FFM ; W = watts.     
There were no significant differences in any of the baseline power values among the three IGF1 promoter genotype groups,     



















Table 7b. Change in peak power with ST by IGF1 genotype in Caucasians.       
    192  Homozygotes  192 Heterozygotes  All other Genotypes 
            
Absolute Peak Power (W)    6.0 ± 12.8 (17)  29.9 ± 10.6 (25)  39.2 ± 17.7 (9) 
 
Relative Peak Power at 50% of 1 RM (W)   17.2 ± 12.9 (15)  23.8 ± 10.9 (21)  26.8 ± 18.2 (8) 
 
Relative Peak Power at 60% of 1 RM (W)   4.7 ± 9.8 (14)  21.6 ± 11.3 (23)  12.3 ± 17.7 (8) 
 
Relative Peak Power at 70% of 1 RM (W)   6.2 ± 9.9 (21)  18.1 ± 8.7 (28)  11.6 ± 17.9 (7) 
 
Relative Overall highest Peak Power (W)     17.7 ± 9.8 (22)   24.9 ± 8.3 (31)   24.9 ± 15.8 (9) 
 Values are least-square means ± SEM (n) when covarying for age, sex and baseline FFM ; W = watts.     
Absolute and relative peak power change scores did not differ significantly among the IGF1 promoter genotype groups when 
















Table 7c. Baseline differences in peak power in the trained leg by IGF1 genotype in African-Americans.        
      192  Homozygotes  1   192 Heterozygotes  All other Genotypes 
              
Relative Peak Power at 50% of 1 RM (W)   262.1 ± 44.1 (3)  314.1 ± 28.4 (7)  363.7 ± 25.3 (8) 
 
Relative Peak Power at 60% of 1 RM (W)   236.2 ± 48.4 (3)  321.9 ± 31.2 (7)  369.9 ± 27.9 (8) 
 
Relative Peak Power at 70% of 1 RM (W)   224.9 ± 44.8* (4)  307.2 ± 29.8 (8)  370.7 ± 25.7 (10) 
 
Relative Overall highest Peak Power (W)     261.5 ± 40.7* (4)   322.9 ± 27.1 (8)   391.3 ± 23.3 (10) 
 Values are least-square means ± SEM (n) when covarying for age, sex and baseline FFM ; W = watts.     





















Table 7d. Change in peak power with ST by IGF1 genotype in African-Americans.       
      192  Homozygotes  192 Heterozygotes  All other Genotypes 
              
Absolute Peak Power (W)    81.4 ± 21.9* (3)  0.8 ± 20.7 (5)  12.1 ± 14.7 (6) 
 
Relative Peak Power at 50% of 1 RM (W)   61.9 ± 20.5 (3)  22.7 ± 25.2 (3)  7.8 ± 12.6 (7) 
 
Relative Peak Power at 60% of 1 RM (W)   59.1 ± 17.9* (3)  9.9 ± 22.0 (3)  20.8 ± 11.0 (7) 
 
Relative Peak Power at 70% of 1 RM (W)   38.4 ± 40.1 (3)  53.3 ± 27.5 (5)  15.0 ± 22.8 (8) 
 
Relative Overall highest Peak Power (W)     27.2 ± 28.4 (3)   59.0 ± 20.1 (5)   4.7 ± 15.3 (9) 
 Values are least-square means ± SEM (n) when covarying for age, sex and baseline FFM ; W = watts.     









APPENDIX A:  
RESEARCH HYPOTHESES, SIGNIFICANCE, 




1. IGF1 genotype will be significantly associated with variation in baseline knee 
extensor peak power in older adults. 
2. IGF1 genotype will be significantly associated with changes in absolute and 
relative knee extensor peak power after 10 weeks of ST in older adults. 
Significance 
       The results of this study when combined with those from other studies will help 
generate new hypotheses for a better understanding of the role of genetics in muscle 
power development.  The ultimate goal of this area of research will be to provide 
better screening procedures and individualized exercise prescription for the 
prevention and treatment of sarcopenia, but achieving this goal will require many 
more future studies. 
Delimitations  
1. The subject pool will be delimited to approximately 114 older men and 
women between the ages of 50 and 85 years who volunteer as study 
participants and whose IGF1 genotype data is available. 
2. Participation in the study will be limited to healthy participants free of 
musculoskeletal or cardiovascular disease who live within 20 minutes of our 




3. Based on previous research, subjects will be divided into three genotype 
groups for determining the effect of the IGF1 promoter polymorphism: 192 
homozygotes, 192 heterozygotes, or non-carriers of the 192 allele. 
Limitations  
1. Due to the longitudinal design of the investigation and multiple variables 
within each genotype group, most of the dependent variables have some 
missing data points.  Therefore, sample size will vary among the various 
dependent variables from 57 to 99.  
2. Study participants will be volunteers and not randomly selected from the 
general population.  As such there may be selection biases that diminish the 
ability to generalize the results of the study to individuals who do not conform 
to the sample population’s characteristics, such as age, race, gender, body 
size, physical activity, motivation levels, etc.  
3. Subjects will self-report many factors related to health and lifestyle such as 
physical activity habits, dietary habits, medication regimens, and medical 
conditions.  Because the accuracy of these reports cannot be verified, it is 
possible that inaccurate self-reports may occur, which could adversely affect 
the results of this study. 
4. It will not be possible to verify compliance of factors that are not being self 
reported, but are part of what subjects are asked to do outside of training 





5. Genotypes other than the IGF1 cytosine adenine (CA) dinucleotide repeat 
polymorphism will not be assessed in the proposed study.  It is possible that 
the IGF1 polymorphism effects are present only in the presence of a specific, 
but unknown, genetic background (epistasis). 
6.  Polymorphisms in the regions flanking the IGF1 gene will not be identified 
or assessed in the genomic material for this study.  It is therefore possible that 
any reported genotype effect is due to linkage disequilibrium between the 
IGF1 cytosine adenine (CA) dinucleotide repeat polymorphism and a distinct 
and putative polymorphism at another locus within the same chromosome.    
Operational Definitions 
1. 1-RM: Refers to the maximal resistance that could be moved a single time 
through the full range of motion (ROM) with proper form.  
2. 5-RM: Refers to the maximum amount of resistance an individual can move 
through a complete range of motion only five times. 
3. CA dinucleotide repeat polymorphism (IGF1 gene): This polymorphism is 
identified by the length of a CA dinuceotide repeat found in the promoter 
region of the IGF1 gene.  It can be 16 to 22 dinucleotides in length (99% of 
population) and is located at nucleotide position 1087 – 1127 in the human 
IGF1 DNA sequence in the original human IGF1 DNA sequence Genbank 
accession number AY260957. RS# 10665874.  For the IGF1 promoter 
polymorphism, subjects would be classified into 3 genotype groups as 
previously reported in the literature: 192 homozygotes, 192 heterozygotes or 




4. Computed tomography (CT): A technique for assessing regional muscle 
size based on the examination of axial scans of the thigh.  Visual images are 
created from the measurement of the intensity of x-rays and analyzed to 
measure cross-sectional area.  The images are based on the attenuation of x-
rays as they pass through the body.  Attenuation scores are measured in 
Hounsfield units, which depend upon the level of absorption of emitted x-ray 
beams, -1000 air to +1000 bone.  Skeletal muscle is typically 0 to 100 and 
adipose tissue is usually -190 to -30. 
5. Functional abilities: An individual’s capacity to perform activities of daily 
living such as walking up and down a flight of stairs or carrying groceries. 
6. IGF1 gene: IGF1 is located on chromosome 12 ( 12q22-q24.1), and contains 
6 exons, four of which are subject to alternative splicing. 
7. IGF-I protein: Human IGF-I is a 70-residue polypeptide with growth-
promoting and metabolic actions.  It is present in both non-muscle and muscle 
tissues. Skeletal muscle is known to be affected by the autocrine/paracrine 
action of IGF-I.  
8. Lengthening phase: Formally called the eccentric phase.  The phase of 
muscle action in which the muscle lengthens as it resists the external forces of 
the knee extension machine, as exemplified in this study by slowly lowering 
the lower leg (knee flexion) after a full range of motion has been reached for 
the knee extension exercise. 
9. Muscle Power: Calculated as the product of torque and angular velocity and 




distance from the knee joint to the force sensor (0.34925 m) and reported in 
N-m.  Angular velocity is reported as rad ∙ s
-1
. 
10. Muscle volume: Total quadriceps muscle volume will be determined by 
Medical Image Processing, Analysis, and Visualisation (MIPAV) software 
through the utilization of 8-11 axial thigh slices obtained from the CT scan. 
11. Range of motion (ROM): The full ROM would be set at 165 degrees of knee 
extension. 
12. Rating of perceived exertion (RPE): A subjective determination of how 
much effort the subject feels they are exerting.  A 6-20 scale would be used 
with 6 being very, very light work, and 20 the hardest possible work. 
13. Sarcopenia: A condition characterized by the loss of muscle size, quality, and 
function that occurs with aging. This typically leads to or exacerbates ailments 
such as osteoporosis and loss of functional independence. 
14. Sedentary: A description for individuals who are not physically active.  In the 
proposed study this term describes individuals who, on average, have 
exercised aerobically for less than 20 minutes per day less than 2 times per 
week and have not performed any type of regular resistance training over the 
past six months. 
15. Shortening phase: Formally called the concentric phase. The phase of muscle 
action in which the muscle shortens as it resists the external forces of the knee 
extension machine, as exemplified in this study by movement of raising the 
lower leg (knee extension) until the subject reaches full range of motion on 




16. Unilateral knee extension (KE) exercise: In the seated position, subjects 
would extend their lower leg against a resistance. Only one leg would be used 





























APPENDIX B:  
LITERATURE REVIEW 
 
     The following review of literature provides background information related to the 
topic of IGF1 gene polymorphisms, muscle power and ST adaptations in older adults. 
This review will focus on the following topics: 1) Causes and consequences of 
sarcopenia, 2) Potential mechanisms of sarcopenia, 3) Muscle power decline with 
age, 4) ST as an intervention against the negative consequences of sarcopenia, 5) 
Variability in muscle size and function in response to aging and ST, 6) Genetic 
variability in muscle phenotypes related to sarcopenia, 7) Physiology of IGF1 
promoter polymorphism and the recommendations for future studies. 
Causes and consequences of sarcopenia.   
     The term sarcopenia comes from the Greek words sarx (flesh) and penia (loss), 
literally meaning loss of flesh.  It refers to the loss of skeletal muscle mass with aging 
which subsequently affects performance and muscle function, including loss of 
strength, muscle quality, and power (156,167,220).  No single factor has been 
identified to explain the aging-related loss of muscle size or function, because 
sarcopenia is a multifactorial condition that occurs naturally with aging, though its 
starting point and consequences vary substantially.  However, there is significant 
inter-individual variability in the magnitude of loss in muscle mass and muscle 
function with age, as well as the factors that explain these losses.  Some of the major 
factors that appear to contribute to sarcopenia are decreases in alpha motor neurons, 
motor units, protein synthesis, expression of myosin heavy chain (MHC), and a rise in 




Hormonal and growth factors include, reductions in the level of sex steroids and 
impairments in the growth hormone (GH)/insulin-like growth factor (IGF) pathway 
(259,277,18,62).  There are also environmental factors, such as nutrition and physical 
inactivity that can have a profound influence on sarcopenia (185,62,205).  
     The first study to define and determine the prevalence of sarcopenia in a large 
group of individuals was the New Mexico study reported by Baumgartner et al (19).  
In this study, sarcopenia was defined as having two SD below the mean appendicular 
muscle mass for healthy young adults.  The authors reported that in elderly Hispanic 
and Caucasian males and females the prevalence of sarcopenia increased from 13 to 
24% of persons aged 65-70 years, to over 50% of those older than 80 years.   In 
addition, sarcopenic women had 3.6 times higher rates of disability, and sarcopenic 
men had 4.1 times higher disability rates compared with study participants with 
normal muscle mass.  In another study in which DXA was used to measure muscle 
mass, Iannuzzi-Sucich et al (124) reported that the prevalence of sarcopenia was 
22.6% for women aged 64-93 years and 26.8% for men aged 64-92 years.  These 
authors also reported that the prevalence of sarcopenia for women and men older than 
80 years was 31% and 45%, respectively.  Similarly, Janssen et al (130) used whole 
body MRI to examine skeletal muscle mass and distribution in a large cohort of 468 
men and women from 18 to 88 yr of age.  They observed a decline in whole body 
skeletal muscle beginning in the third decade; however this loss did not become 
substantial until the end of the fifth decade.  An important finding of this study was 
that the loss of muscle mass with aging was greater in the lower body in men and 




the lower extremity muscles with aging and has important implications for functional 
mobility and disability. 
     In addition to these studies, the losses of muscle mass and muscle function due to 
sarcopenia have been well-documented in several recent cross-sectional and 
longitudinal studies (90,57,134,79,161,165), and have many significant health 
consequences ranging from decreases in functional ability to increased mortality risk. 
These consequences include: increased risk of falls (162,255), hip fractures (5), 
glucose intolerance (25) bone mineral density loss (257,252), and physical disability 
(295).  Most of the studies investigating the functional implications of sarcopenia 
have assessed the relation between lower limb strength or power (or both) and 
function in tasks such as stair climbing, rising from a chair, or walking 
(48,217,26,204,21).  Finally, it has been shown that sarcopenia is associated with 
increased mortality(180,181,182).  Miller et al (182) showed that corrected  arm 
muscle area is a better predictor of long term mortality than BMI, which is often used 
as a predictor of mortality in older adults.  Also, several studies have reported an 
association between low muscle strength and increased mortality rates (155,223).  For 
example, Metter et al (180) reported that both grip strength and change in grip 
strength were predictors of mortality, independent of physical activity or muscle 
mass. 
     Using the standard criteria for sarcopenia, Baumgartner et al (19) estimated the 
prevalence of sarcopenia to be about 9 million in the U.S.  With an aging society, this 
is estimated to expand significantly and become a major medical cost.  Demographic 




United States for example, census data has estimated that the number of people 
considered to be aged (>60 years old) will more than double between the years of 
1990 and 2030.  Consequently, health care costs will increase for the elderly. 
Thus with an aging society, it is imperative from a public health perspective to 
address this natural aging process, through a better understanding of its causes, 
prevalence and treatment. 
Potential mechanisms of sarcopenia. 
     No single cause has been identified to explain the decline of muscle size or 
function with age.  Yet, many interrelated factors likely contribute.  A loss of alpha 
motor neurons, declines in testosterone and estrogen, growth hormone, IGF-I, protein 
synthesis, changes in myosin heavy chain (MHC) gene expression, and an elevation 
in catabolic stimuli, including cytokines, are  examples of some of the major factors 
leading to sarcopenia.(153).  
     The total number of central nervous system and muscle neurons is known to 
decrease with age (234,32), resulting in a preferential loss of the fast motor unit 
(61,63).  This results in a reinervation by slow motor units, which transforms them 
into the slow myosin type (63), resulting in an increase in motor unit size and  a 
decrease in the number of fibers that produce high force and velocity.  It can also 
result in reduced force and/or power production of the entire muscle due to the loss of 
the most powerful muscle fibers.  Nevertheless, Urbanchek et al. (287) reported that 
only 11% of the decrease in muscle force production was attributable to denervated 
fibers.  Furthermore, some recent evidence suggests that the loss of motor neurons 




     In addition to the loss of fast motor units, muscle contractile and mitochondrial 
protein synthesis rates decline with aging (8,193,235,154), as do whole body muscle 
protein synthesis rates and MHC levels (8,300,109).  Also, several hormones such as 
testosterone, estrogen, growth hormone, and IGF-I  have an anabolic effect on 
muscle, and decrease with age (13,285,106,213,293).  Moreover, catabolic stimuli, 
including cytokines, increase with aging (241,264). 
Muscle power decline with age.  
 
     Muscle power (i.e., the rate of force production) accounts for a greater amount of 
the variance in physical performance than strength in older adults (21,79) and 
deteriorates at a faster rate than strength with advancing age (16,179,260).  Although 
the literature is not as extensive for investigating muscle power losses as strength 
losses with aging, recent studies have focused on the changes in power with aging 
and with exercise training.  Most recent aging studies, showing a greater decline in 
maximal power than decline in isometric and dynamic strength have used derivatives 
of the Hill’s (1938) equation to calculate power from the f-v relationship 
(194,271,278), but have not directly measured movement velocity, an important 
component of power. 
     This lack of data on muscle power and the elderly is partially attributable to the 
difficulty in safely and accurately measuring power (66).  The use of isokinetic 
dynamometers allow for power to be estimated in a single muscle group based on 
peak torque, but this measurement does not consider the power needed to accomplish 
daily tasks at various external resistances and overcome speed (167).  Because 




tested, the velocity component of power is not directly assessed with isokinetic, 
which explains why data is lacking for power losses with aging.  In addition, elevated 
antagonist muscle activity in the elderly may limit the full movement efficiency 
depending on the type of muscle contraction and the movement velocity.  Earlier 
measurement of power employed vertical jumping from a force platform (72,92), 
which functioned similar to a scale, whereby muscle power is the product of force 
(after subtraction of body weight from the vertical component of the ground reaction 
force) and the movement velocity.  This type of measurement may not be safe for 
older adults.  Moreover, the subject must move his/her body mass, which likely 
represents a higher than optimal external load for peak power production based on the 
force-velocity curve (167).  The nature of the force/ velocity relationship dictates that 
power will have its own distinct relationships with force and velocity of movement. 
Thus, there is an optimum force and an optimum velocity at which maximum power 
is developed. In isolated animal muscle, these correspond to  about 30% of Po and 25-
30% of Vmax, respectively (167).  However, measurements of force and velocity and 
power/velocity relationships in humans in vivo represent the resultant of relatively 
complex situations, as human muscles are attached to bones via tendons that cross 
over one or two articular joints in order to produce movement.  Not only must the 
contractile elements of muscle cells be considered, but also factors such as neural 
influences, muscle architecture and intracellular connective tissue.  The optimal 
values of force and speed for maximum power production in vivo may therefore be 




     The aforementioned difficulty in safely and accurately measuring power (167) was 
addressed in several investigations (66,76,127,134) reporting peak power as the 
highest average power obtained during multiple trials of a power test, as opposed to 
the highest power value attained during a single trial.  The highest peak power (i.e., 
the highest combination of force and velocity that occurs simultaneously during a 
single trial) might be a more accurate measure of the explosive capacity of the trained 
musculature than average (area under curve) power of a single trial.  This is because 
average power includes two phases of movement that represent reduced power.  The 
first is at the beginning of the movement when one is trying to overcome inertial 
forces and the other is near the end of the movement when co-contraction of the 
antagonist muscle group produces a reduced force and velocity.  Although some 
previous investigations did exclude data from the first and last 5% of the range of 
movement in the power tests (21,76,79), these studies still used the average power for 
a given trial, and reported it as peak power. 
     To address the safety concerns associated with power testing using a force 
platform, Bassey and Short (17) invented an apparatus that measured average leg 
extensor power from force against a pedal that accelerates a flywheel of known 
inertia.  However, older subjects were still required to use a higher percentage of their 
maximal power capacity because of the fixed inertia characteristic of the apparatus 
(167), but this problem has been since corrected by the development of a variable 
inertia testing apparatus (208).  More recently, Delmonico et al (58) reported the 
measurement of peak power during a single trial, rather than average power 




repetition was performed in older adults by using a machine equipped with load cell 
force transducers and position sensors to detect rotary motion at the joint.  Peak 
power is calculated by filtering power data points during a single knee extension trial 
with a 10
th
 order Butterworth filter.  The use of this dynamic pneumatic resistance 
equipment for the evaluation for muscle power has since then been used for the 
evaluation of muscle power in most recent studies (53,114) and has been shown to be 
a reliable, valid and safe method of muscle power testing in older adults (34). 
     Izquierdo et al (128) determined the optimal loads for maximal power production 
and found that peak power is maximized at 30 – 45% of peak strength for the upper 
extremity and at 60-70% for the lower extremity in middle aged and older adults. 
Moreover, their results confirm previous data showing peak power decreases with 
increasing age to a greater extent than strength.  This work is supported by more 
recent data reported by Macaluso and De Vito (166) who found that maximal peak 
(average) power is obtained at ~ 60% of maximum isometric strength in both young 
and older women, and this peak power is 61% lower in the older women.  They also 
reported that power is influenced to a greater extent with aging than isometric 
strength.  In contrast to these findings, Cuoco et al.(48) reported that lower external 
loads (~ 40% of leg press 1- RM) explained more of the variability in normal gait 
speed in the elderly than did power at higher external loads (~ 70% of 1- RM).  
Habitual gait speed is known to be a predictor of future disability, thus the authors 
suggest that lower external resistances should be used when evaluating peak power in 
older adults (48).  More recently, the study by Puthoff and Nielsen (217) reported that 




previous studies that have reported peak power occurring at 70% of 1- RM or higher 
(21,76,20).  These authors reported that differences in testing protocols used in these 
studies may account for the power value differences; however they recommend that 
future investigators should be cautioned in using power at a predetermined relative 
intensity to represent peak power values for all subjects. 
     Previous cross sectional data suggest that the decline in peak muscle power with 
age is associated with muscle structure and function, tendon characteristics, and 
sarcopenia in specific muscle groups (242).  In that investigation, 169 women and 89 
men between 18 and 88 years were studied, and muscle force and power were 
assessed by jumping mechanography.  These healthy subjects showed a difference of 
> 50% between the ages of 20 and 80 without a reduction in muscle cross sectional 
area suggesting that power declines might central role in the aging process. 
Additionally, because there is a general consensus that the relationship between 
muscle power and function is stronger than that of strength and functional abilities in 
the elderly (21,48,217,269), determining the age-related causes of decreased muscle 
power provides important and relevant information to the understanding of 
sarcopenia.  Bassey et al (16) examined leg extensor power in elderly (~ 88 yrs old) 
patients in a chronic care facility using a custom built rig that measured maximal 
power output over < 1 s of a single extension of one leg.  They found that leg 
extensor power was significantly correlated with all functional ability measures which 
included time taken to rise from a chair, climb a flight of stairs and walk 6.1m.  These 
data agree with findings obtained by Rantanen and Avela (221) that average leg 




mobility impairments in the elderly.  Numerous recent studies have also added to the 
growing body of evidence that power has greater influence over functional capacity 
than strength (21,269,217).  The functional capacity was assessed in these studies 
using various functional performance tests such as chair-rise time, stair-climb time, 
tandem gait, habitual gait, maximum gait and the short physical performance battery 
(SPPB). 
     Cross-sectional and longitudinal data from the BLSA (179) show age-associated 
reductions in power and isometric strength in the upper extremities in men and 
women over an average ~ 10 year period.  Peak arm power was measured in 10 - 15 
sec periods of maximal arm cranking using a bicycle which was converted and 
functioned as a drive shaft to power a generator.  Strength and power declined 
beginning by age 40 in both women and men, but power declines were ~ 10% greater 
than strength losses in men, while no significant declines were found in women.  The 
differences between the changes in power and strength with age in men support the 
hypothesis that there are variables other than strength, such as movement velocity, 
that influence power reductions.  This finding confirmed an earlier study by Skelton 
et al (260) who found that between the ages of 65 and 89 years, power declines at a 
rate of ~ 3 – 4% per year, which is higher than the rate of isometric strength loss (~ 1 
– 2% per year).  Runge et al (242) also reported that there is a significant decrease in 
muscle power between the ages of 20 and 80 years, without a decline in muscle CSA. 
Most recently, Petrella et al (211) examined age and gender differences in knee 
extensor strength and power in young (~ 26 yr old) and older (~ 63 yr old) men and 




the young and older subjects, and there was also a significant difference between age 
groups in knee extension power when normalized for thigh muscle mass.  In addition, 
older adults had a significant decrease in peak velocity over 10 repetitions of knee 
extension exercise, indicating that attenuation of velocity in older adults may likely 
be a contributing factor for decreases in power.  This decrease in velocity may also 
contribute to increased risk of falls and mobility loss in the elderly. 
     Aging-related declines in muscle strength and power are related to changes in the 
number of motor units, lower muscle fascicle length and  pennation angle, increases 
in connective tissue and fat infiltration, fiber type grouping, loss of type II fibers, and 
decreased expression of myosin heavy chain (MHC) proteins 
(8,141,151,159,187,195,271).  The mechanisms that cause a more rapid decrease in 
power than strength with aging are not yet fully understood.  However, because 
power is the product of force and velocity, variables that influence either of these two 
factors will affect peak power (167).  Thus, many of the mechanisms that influence 
muscle strength decline with aging are likely to be at least partially responsible for the 
related decreases in power with advancing age.  Additionally, specific changes that 
might influence muscle contraction speed will have a more significant impact on peak 
power than strength.  For example, with aging there is a preferential loss of type II 
skeletal muscle fiber number and size.  However, according to a recent study by 
D’Antona et al. (50), this selective atrophy of type II muscle fibers, is caused by the 
decrease in physical activity that occurs with aging, rather than aging per se. 
Furthermore, older skeletal muscle has been shown to be more likely to express more 




studies report that type II skeletal muscle fibers are capable of a four-fold greater 
power and force output and a faster shortening speed than type I fibers (167).  The 
loss of type II fiber size leads to the decreased expression of fast MHC isoforms, 
which would likely have a significant impact on power output (108), and supports the 
evidence of change from fast to slow motor units with aging (291). 
     Other potential mechanisms have also been identified, which include increased 
tendon stiffness with aging (167) and neural influences, which include dopaminergic 
neuron loss in the substantia nigra.  This could result in a decrease in coordination, 
movement speed, and power.  Furthermore, decreases in the sliding speed of actin on 
myosin with aging may play an important role in the observed power decline with 
advancing age. For example, Hook et al (117) reported an 18 – 25% age-associated 
reduction in the speed of actin filaments on myosin from 62 single fibers.  The 
mechanisms underlying the aging-related slowing of motility speed remain unknown, 
but it is hypothesized that posttranslational modifications of myosin by oxidative 
stress, glycosylation, or variations in muscle protein expression might explain this 
decline in the intrinsic speed of the myosin molecule with age.  In addition, a recent 
study by Thom et al (271) reported that fascicle shortening and the associated loss of 
sarcomeres in series is thought to account for a significant portion of the decline in 
muscle power observed in old age. 
ST as an intervention against the negative consequences of sarcopenia. 
     As a result of the increased prevalence of sarcopenia, the resulting health care 
costs and detrimental physical consequences, it is imperative from a public health 




sarcopenia, without the adverse side effects of many pharmacological interventions. 
Recent reports indicate that the administration of growth hormone, one of the more 
commonly recommended interventions for sarcopenia, should not be used for this 
purpose due to its untoward side effects and questionable efficacy (24,190).  
Therefore, until future research suggests otherwise, ST should be the intervention of 
choice for sarcopenia due to the substantial evidence for its efficacy within a very 
short time frame and safety (121,214,122,238,74).  Several training studies have 
shown the efficacy of ST in increasing muscle strength and muscle mass in men and 
women aged 50-98 yrs (258,74,126,147,82).  Some ST studies in older adults have 
also examined the muscle function changes that occur at the muscle fiber level.  Data 
show that type I and type II muscle fibers in older adults maintain the ability to 
undergo hypertrophy with ST (44,82,97), but some investigations found that there 
was only slight or no change in fiber areas (94,120).  Changes in fiber size with ST 
are ~ 10%, which is typically greater than at the level of a whole muscle group.  This 
may be at least partly because MRI and CT assessment of whole muscles or muscle 
groups also measures other tissues (e.g. connective tissue), which are not apt to 
experience the same magnitude of change as muscle tissue.  In addition several 
studies have found evidence for MHC II subtype transformations with ST in older 
adults, with MHC IIb changing to IIab to IIa, which is a similar response that occurs 
in younger adults (98,108,254).  However, one investigation reported an increase in 
MHC I expression with ST (302), which could be attributed to a lower intensity 
training protocol in that investigation.  It has been suggested that this lower intensity 




optimal increases in MHC II expression.  At the muscle fiber level, Trappe et al 
(282,284) ) found that in older men and women, skeletal muscle fibers increase in 
size, strength, and power with 12 weeks of ST.  Other investigations report increases 
in protein synthesis in older adults with ST along with improvement in strength 
(109,300).  Muscle quality (i.e. strength per unit of muscle mass) has been shown to 
improve with ST in older adults (126,280,300).  Moreover, as muscle architecture 
plays an important biomechanical role in the ability of the muscle to produce force, 
the effect of resistance exercise on muscle architecture in older adults has been 
examined in numerous recent studies (188,225,226,265).  The recurrent finding is that 
there is an increase in muscle fascicle pennation angle following resistance exercise, 
which means that more sarcomeres are added in parallel, allowing muscles to produce 
more force across all concentric contraction speeds.  There is contradictory evidence, 
however with regards to whether muscle fascicle length of older adults changes 
following resistance exercise, with one study showing no change (188) and others 
finding an increase in fascicle length (226,225).  Finally, the muscle adaptations due 
to ST have been shown to positively affect functional ability in elderly men and 
women (244,69).Because muscle power accounts for a greater percentage of the 
variance in functional abilities than strength (21,79) and deteriorates at a faster rate 
than strength with advancing age (16,179,260), recent studies have more often 
focused on the effect of ST on muscle power (20,58,66,73,76,97,134,112,53,227,28). 
     A randomized study by Earles et al (66) compared the effects of a high-velocity 
ST program combined with moderate non-resistive exercise to an intervention of 




of 70.Power improved significantly in the high-velocity ST group only for leg press 
(22%) and knee extension (increases of 50%, 77%, and 141% when power was tested 
at external resistances of 50%, 60%, and 70% of body weight, respectively).  
However, these improvements in power did not lead to improvements in functional 
abilities, although their cohort was considered high functioning at baseline.  A more 
recent randomized study by Fielding et al. (76) examined 30 older women with mild 
functional limitations and compared the changes in skeletal muscle power between 16 
weeks of high-velocity ST and a more traditional, low-velocity ST intervention.  The 
results indicate that although leg press and knee extensor 1-RM strength increased 
similarly in both groups with ST, leg press peak power increased significantly more 
in a high-velocity group (97%) than in a low-velocity group (45%).  The conclusion 
was that higher-velocity training programs might be more efficacious for increasing 
peak power in older individuals with functional impairments. These data agree with 
recent findings that a 10-week power training (PT) program (three 8-10 repetition sets 
performed as fast a possible at 60% of 1-RM) produced greater improvement in 
muscular power and functional performance than the traditional resistance training 
(TRT) (three 8-10 repetition sets with 2-3 s contractions at 60% of 1-RM) in older 
men (28).  
     In contrast to the above findings a recent study by Henwood et al. (112) observed 
similar improvements in maximal strength, peak and average muscle power, and 
functional performance after traditional resistance and high velocity varied resistance 
training.  These results were similar to the findings of a randomized control trial done 




and traditional slower velocity progressive training yielded similar increases of lower 
extremity power in the mobility-impaired elderly. 
     Moreover, it is still not well established whether a high velocity training program 
is well tolerated by older subjects (68) especially subjects who are frail and could 
benefit the most from increased muscle power.  Furthermore, most power training 
studies done in older adults have reported several adverse events.  One study, for 
example, reported a case of disc herniation that may have resulted from the training 
program (66).  Other injuries include back pain (66), exacerbation of pre-existing 
osteoarthritis (76,113,53), minor strains (53), tendonitis (53), plantar fasciitis (76) and 
unspecified injuries leading to drop-out (184).  A recent power-training study done 
with the largest group of subjects ( n =112), reported that since all the training injuries 
occurred during high-load (80% of 1-RM) training, lower-load training (50% 1-RM) 
might be undertaken to reduce the risk of injury, even though the benefits to strength 
and endurance might be lower. 
     Several studies that examined peak power used lower-velocity ST protocols that 
have extensive track records for being generally safe for older subjects (75,134,261).  
In these investigations, muscle power increased significantly with ST, ranging from ~ 
18 – 28%, lower than some studies using higher velocities (184,28), though the 
increases in strength were greater due to specificity of training.  
In an earlier investigation, Fiatarone et al.(75) conducted a randomized, 
placebo-controlled trial comparing ST, multinutrient supplementation, both 
interventions, and neither in 100 frail nursing home residents over a 10-week period. 




compared with the non-exerciser group (28.4% vs. 3.6%).  These data indicated that 
there is a relationship between power adaptations to ST and functional ability.  That 
study was followed by a report by Skelton et al (261), who found that in 20 relatively 
healthy, independent elderly (76 to 93 years) women, knee extension power increased 
by 18% (as measured by the Nottingham Power Rig developed by Bassey and Short 
(17) when adjusted for body weight.  More recent data reported by De Vito et al.(54) 
examined the effects of a 12 week of a low-intensity general conditioning program on 
maximal power in 20 elderly women (~ 63 yrs) randomized to a training or control 
group. Peak power was determined at baseline and after the training regimen via 
vertical jump on a force platform.  Peak power increased significantly in the training 
group, but did not change in the control group.  The authors suggested that this 
increase in power could be due to improvements in neuromuscular activation.  
Additionally, Jozsi et al.(134) reported that with ST in men and women age 56-66 
years, there was an increase in knee extensor and arm flexor power with ST of 30% 
and 18%, respectively.  These increases in peak power were independent of age or 
sex and occurred at 40% and 60% of 1 RM, and were similar to the changes observed 
in younger subjects.  Izquierdo et al. (127) also reported that 16 weeks of ST resulted 
in large gains in strength and power load characteristics of the upper and lower 
extremity musculature, but the pattern of strength and power development seemed to 
differ between the upper and lower extremities in middle aged and older men. These 
studies, when taken together, suggest that both traditional and higher-velocity ST 




       Earlier reports (66,76,127,134) on the effects of strength training (ST) on muscle 
power also did not report how the training affected power per unit of the muscle 
involvement (muscle power quality, MPQ), or peak movement velocity (PV), the 
latter possibly being an important component of power and possibly functional 
abilities in the elderly. The expression of peak power and PV normalized for muscle 
volume allows better understanding of potential mechanisms (e.g., hypertrophy and 
neuromuscular adaptations) for training-induced adaptations.  It is also important 
when comparing groups who possess different amounts of muscle mass, such as men 
compared to women.  Most recently, Delmonico et al.(58) reported the effects of a 
10-wk, moderate velocity ST intervention on peak knee extensor power in relatively 
healthy older men (n = 30) and women (n = 32).  Results showed that peak power 
(PP) increased significantly in both men and women at the same absolute (same 
absolute resistance before and after ST) and relative (70% of 1 RM at baseline and 
70% of the improved 1 RM after ST) external loads.  In addition, men and women 
both increased their absolute peak movement velocity with ST, and there was a 
significant 9% training-induced increase in MPQ in women, but no change in men. 
This latter finding indicates that women may not rely on muscle hypertrophy as much 
as men to improve muscle function with training.  This could possibly be due to some 
type of neuromuscular adaptation that compensates for the reduced capacity of 
women to undergo muscle hypertrophy with ST compared to men, resulting in a 
compensatory increase in power per unit of muscle.  Support of a sex difference in 
MPQ comes from work by Trappe et al.(283,282) ) who found that the response of 




shortening velocity differ with the same training stimulus between men and women. 
However, no change in muscle fiber unloaded shortening velocity or normalized peak 
power was found in older women, indicating a sex difference in response to ST, 
although the cause for this difference is unclear. 
     Muscle power is a more complex phenotype than strength, thus there may be more 
interrelated factors that influence peak power changes with ST than are responsible 
for muscle strength changes alone.  First, there are possible preferential increases in 
type II fibers leading to overall increases in muscle mass, which in turn leads to 
enhanced force production and muscle fiber shortening (76).  Previous data has 
shown that adaptations to single MUs can help increase contraction speed with ST 
(290).  Changes in MU function consist of earlier activation, shorter interspike 
intervals, and increased maximal firing rate (290).  In addition, neural adaptations, 
including increased activation of the agonist muscle groups, decreased co-activation 
of the antagonist muscle groups, improved coordination and activation of synergistic 
muscles, and increased neural drive from the CNS, might lead to improvement in 
power with ST (167,84).  Nevertheless, it may be problematic to directly examine 
these potential neurological components during power testing using 
electrophysiological methods because there are a host of physiological, mechanical, 
and electrical changes that happen during the contraction that might impact the 
correlation between signal amplitude and muscular force (167).  Finally, tendon 
stiffness may be affected by ST, which may affect power changes.  Maganaris et al 
(168) used an in vivo method for assessing tendon stiffness in older adults, and found 




14-week ST intervention.  The rate of muscle torque production also increased by ~ 
27%, indicating that there is a faster contractile force transmission to the skeleton. 
Also since age differences in power persist even after accounting for muscle size, 
primarily from deficits in movement velocity (55,211) some studies have also 
examined changes in movement velocity using progressive resistance exercise as a 
stimulus and reported significant improvements (58,66,166).  A recent study by 
Petrella et al (210) reported that the gains in concentric peak power during 16 weeks 
of progressive resistance exercise were differentially driven by gains in force and/or 
velocity among age groups.  Of the components of peak power (force and velocity), 
marked improvements were found in both force and velocity among older adults 
while young adults only improved force (strength). 
     These data provide support for several mechanisms that might play a role in the 
changes in power with ST.  However, there appears to be a great deal of inter-
individual variability in the rate of decline in muscle mass and muscle function with 
aging, that contributes to the age related differences in power (172).  A recent study 
by Kostka et al (148) reported that age contributed to the variability in quadriceps 
maximal short-term power, independent to quadriceps mass and optimal shortening 
velocity, probably reflective of age-related impairment of neural control to the 
muscular function and an increase in the proportion of connective tissue within the 
muscle (3). 
Variability in muscle size and function in response to aging and ST. 
     Studies have demonstrated great inter-individual variability in the loss of muscle 




for physical activity levels (165).  Moreover, muscle mass, strength, and power 
responses to ST vary substantially among individuals.  In a previous investigation 
from our lab, after only nine weeks of a highly standardized quadriceps strength 
training program in a healthy and homogeneous group of 65 to 75 year old men and 
women,  knee extension strength gains with ST  ranged from 5 to 86 pounds (125). 
Muscle power changes with ST also are quite variable, with  peak power ranging 
from – 19 to 126 W at the same absolute resistance, and peak movement velocity 
changes ranging from -1.1 to 2.7 rad/sec at the same absolute resistance (58).  These 
data indicate that there are large inter-individual variations in muscle changes even in 
response to very short term, highly standardized strength training interventions. 
Studies here have also reported increases in quadriceps muscle volume with ST that 
range from 19 to 344 cm, further demonstrating the wide variation of inter-individual 
changes in muscle mass from ST (125).  This large inter-individual variability and the 
fact that twin studies show that a major portion of the variance in strength and muscle 
mass can be accounted for by heredity, suggest that heredity and specific gene 
polymorphisms may explain a large portion of inter-individual differences in 
responses to ST. 
Genetic variability in muscle phenotypes related to sarcopenia.  
     Results from heritability studies, genome wide scans, and candidate gene studies 
have suggested the presence of a genetic influence on baseline and ST-induced 
muscle phenotypes.  The estimation of heritability of a specific trait is commonly 
estimated by the study in twins and families.  The most common analysis of 




dizygotic twins.  If a trait is completely determined by genetics, there would be 
correlation of 1.00 between sets of monozygotic twins, but a correlation of only ~ 
0.50 between dizygotic twins, because dizygotic twins only share ~ 50% of their 
genetic makeup.  However, skeletal muscle phenotypes are also influenced by many 
other factors beyond genetics, which can have an effect on the heritability estimate. 
Factors such as shared/non-shared environmental factors, additive/dominant genetic 
effects, and measurement error can influence these heritability estimates. 
     Several heritability studies have shown the influence of genetics on fat-free mass 
(FFM) at baseline.  Bouchard et al (29), for example, estimated the transmissible 
variance of familial resemblance for FFM to be 40-50% in subjects from the Quebec 
Family Study.  Other studies performed on monozygotic (MZ) and dizygotic (DZ) 
twin pairs have shown that the heritability in lean body mass ranges from 52-80% 
(6,198,251).  A more recent twin data study in adults confirmed these heritability 
values from previous studies by reporting a  heritability estimate of 77% for FFM in 
both men and women (105).  Age and sex did not appear to be significant covariates 
of within pair differences.  In contrast, a more recent heritability study on skeletal 
muscle traits in subjects of African descent reported that heritability may differ as a 
function of sex and age (215).   In this study, the age-specific analysis showed that the 
heritability of leg lean mass was lower in older vs. younger individuals (h(2) = 0.05 
vs. 0.23, respectively, P = 0.1).  Also, sex was a significant covariate in the models (P 
< 0.001), although sex-specific differences in heritability varied depending on the 
lean mass phenotype analyzed.  Another heritability study by Huygens et al. (123) 




the variance in baseline muscle mass is heritable in young male twins.  With regard to 
skeletal muscle fiber composition, earlier heritability estimates suggest that muscle 
fiber type composition is over 90% genetically determined (146), but later studies 
indicate it is only around 45% (256).  In addition, skeletal muscle enzyme activity 
also seems to be somewhat heritable, with estimates of 25 – 50% when adjusted for 
age and sex (30). 
     Twin studies indicate that strength has a moderate to high heritability, with 
different studies reporting a range of 30 – 80% depending on the population studied. 
Frederiksen et al (81) reported that in 1,757 Danish twin pairs aged 45 - 96 years, 
handgrip strength heritability is 52% but can be as high as 62% when examining only 
healthy twin pairs from the cohort. Grip strength has been shown to correlate strongly 
with other muscle groups with respect to strength and power.  Men and women were 
used in this analysis and age was stratified into quartiles in the model.  Results further 
indicated that a large portion of the variance is explained by additive genetic effects 
and non-shared environmental factors.  In addition, there was no significant influence 
of age or sex in this analysis, indicating that these variables were not confounders or 
effect modifiers in this study.  This heritability estimate is higher than previous data 
from postmenopausal female twins that indicate a heritability estimate of 30% (6).  
Other data on strength in older male twins indicated a heritability of 65% at baseline, 
but when shared environmental factors were included in the model, this estimate 
dropped to 35% (39).  A 10-year follow up indicated a heritability estimate of only 
22% (39).  More recently, Tiainen et al (274) indicated that handgrip and knee 




variance in older female twins.  Furthermore, additive genetic effects accounted for 
46% of the variance in knee extension strength.   
     Although there is currently insufficient  data to make any definitive conclusions 
concerning the contribution of  heritability to  the loss of muscle power with aging, 
recent evidence suggests that knee extensor strength and power share a common 
genetic component (274).  Data from the Finnish Twin Study on Aging, examined the 
genetic component of maximal voluntary knee extension power and strength in 101 
monozygotic (MZ) and 116 dizygotic (DZ) female twin pairs aged 63 – 76 yr (273).  
Results indicate that a common genetic factor accounted for 32% of the total variance 
in leg extensor power and only 4% of the variance in power is attributable to non-
shared environmental factors.  The results of a 3 year follow-up study reported  by the 
same investigators  examined the changes in the contribution of genetic and 
environmental influences on  isometric knee extensor strength and leg extensor 
power, among 63- to 76-year-old female twins, indicating that the contribution of 
genetic influences  on  isometric muscle strength was stable, whereas for leg extensor 
power the proportion of genetic influences  decreased during the follow-up (275).  
The authors observed new specific environmental effects underlying follow-up 
muscle strength and power, which effects could be due to the onset of new disease 
processes or changes in lifestyle.  
      Additional evidence from twin studies  indicate a  heritability estimate of .84 for 
muscle power using  a 5s Wingate cycle test (35).  Most previous studies have 
estimated heritability values using standing long jump, vertical jump and distance 




heritability values from twins and siblings 3 through 42 years of age range from 0.14 
to 0.91  (169,270).  Further these studies revealed that the sex differences in 
heritability are not as apparent as for strength.  Parent offspring data for explosive 
strength (power) tasks are quite limited, probably reflective of the task demands and 
age associated decrements in performance on such tasks during adulthood. Thus, 
many more studies will need to be done in order to more accurately determine the 
heritability of the explosive type of skeletal muscle power and the heritability of its 
decline with aging. 
     Few genome-wide scans or linkage studies have been reported  identifying genes 
or gene regions that may influence muscle phenotypes at baseline or after ST. 
Chagnon et al.(42) performed a genome-wide search for genes related to body 
composition and its changes after a 20-wk endurance-exercise training program. 
These researchers found evidence of significant linkage with changes in FFM and the 
IGF1 gene.  Huygens et al (123) explored the potential role of the myostatin pathway 
in relation to muscle strength and estimated muscle CSA in humans using linkage 
analysis with a candidate gene approach.  Linkage patterns were observed between 
knee extension and flexion peak torque with markers corresponding to the myostatin 
gene, the CDKN1A gene, and the MYOD1 gene with a maximum LOD score of 2.63 
observed with the myostatin gene.  Another recent  genome-wide linkage analysis 
study by Karasik et al (137), identified two loci with LOD scores >3.0, shared by leg 
lean mass with femoral bone geometry on chromosome 12p12.3-12p13.2 and on 
14q21.3-22.1.  With regards to muscle power, there is a paucity of whole genome 




analysis showed that the chromosome areas of suggestive linkage for strength and 
power partly overlapped, with the LOD scores higher than 1.0 being seen for these 
phenotypes on chromosome 15 (276). 
     In addition to the genetic influence on muscle phenotypes at baseline, the 
aforementioned variability of muscle response to a standardized ST protocol suggests 
that heritability may influence the response of muscle phenotypes to ST, although 
probably accounting for a smaller percent of the variance. Further evidence for this 
comes from a study by Thomis et al. (272), in which they investigated the heritability 
of changes in arm strength after 10 weeks of ST in young male MZ and DZ twins. 
They observed a genotype by training interaction for one-repetition maximum (1-
RM) strength and isometric strength with MZ intra-pair correlations of 0.46 and 0.30, 
respectively.  Twenty percent of the variation in post-training 1-RM strength, 
isometric strength, and concentric moment at 120 degrees/sec was explained by 
training-specific genetic factors that were independent from those that explained 
variation in the pre-training phenotype (30-77%). 
     Thus, it appears that although genetic factors do account for a proportion of 
variability in muscle phenotypes at baseline and in response to strength training, the 
identification of specific contributing genes is complex.  A primary strategy is to 
identify biologically plausible genes and conduct gene association studies, with the 
ultimate goal of reconciling the complex interplay of genetic and non genetic factors. 
      Despite the importance of muscle power as an important muscle phenotype 
especially in the elderly, there are few genetic studies that have studied the influence 




older adults, with the only exception being Alpha actinin 3 (ACTN3) and its 
premature stop codon at the R577X locus.  Several cross sectional studies have shown 
that the X/X genotype in the ACTN3 gene is significantly less frequent among elite 
power athletes compared to endurance athletes and to non-athletes (309,310,200,315), 
suggesting that the X/X genotype is associated with low power.  The current research 
literature on genes influencing power adaptations to ST is extremely scarce. One 
recent study that examined knee extensor concentric peak power before and after 10-
wk ST intervention in 157 older men and women reported that the ACTN3  R577X 
polymorphism influences the response of quadriceps muscle power in older adults 
(59).  In this study, in women the X/X carriers exhibited a lower change in relative 
peak power in response to training compared with the R/R group.  In men, the change 
in absolute peak power in response to training tended to be higher in the R/R group 
compared with the X/X genotypes. 
      Further given that muscle power is a complex multi-factorial clinically important 
phenotype and would be influenced by several genes in several different pathways, 
identifying the physiologically relevant genes that could influence muscle power at 
baseline and in response to ST would be useful.  
Physiology of IGF1 promoter polymorphism and the recommendations for 
future studies. 
      The IGF1 gene, that encodes for the IGF-I protein, is located on human 
chromosome 12 (12q22-q24.1) (189) and consists of 88,066 base pairs.  This gene 
contains two known promoters, six exons, and five introns (262).  Depending on the 




acids and is eventually translated into a 70 amino acid protein with three disulfide 
bridges (160).  The mRNA can produce at least three different transcripts, two of 
which are expressed in skeletal muscle (176,240,14). 
     The somatomedin hypothesis came from early experiments trying to understand 
somatic growth caused by the pituitary gland.  Results from these experiments 
suggested that growth hormone (GH) may be playing a role in somatic growth 
indirectly by modulating levels of mediating growth factors, designated as 
somatomedin substance (52,191,243).  Insulin-like growth factor-I (IGF-I) was 
eventually purified from rat serum and shown to be the samotomedin substance 
regulated by GH (230).  It was termed “insulin-like” because of its ability to stimulate 
glucose uptake into fat and muscle cells, as well as its homology in amino acid 
sequence with insulin (230).  Upon the discovery of IGF-I, the somatomedin 
hypothesis was further refined to suggest that GH secreted by the pituitary would act 
on the liver as its target organ, where IGF-I would be secreted to act on bodily tissues 
causing growth and provide feedback to the pituitary to control the level of GH 
secretion. 
     The first indication that the somatomedin hypothesis was incomplete was when 
D’Ecrole et al (51), discovered that explants of fetal mouse tissue maintained in 
serum-free media showed higher levels of IGF-I in the culture medium than  with 
extracts of the tissues themselves: i.e., liver, intestine, heart, brain, kidney, and lung. 
Additional studies supported the finding of various tissues expressing IGF-I, and that 
this tissue-specific IGF-I could be affected by and also act independent of plasma GH 




question.  It was subsequently shown that GH could affect tissues via stimulating 
local production of IGF-I or act directly on tissues to cause growth (93).  The latter 
process occurred without a mediating factor, but was not as dramatic as when IGF-I 
was involved in the process. 
     Action of IGF-I.  IGF-I displays numerous diverse functions during both 
embryonic development and postnatal growth (233).  Studies have shown that mice 
carrying null mutations in the IGF1 gene are born small and grow poorly postnatally 
(7).  Naturally occurring mutations in the IGF1 gene are rare. It has been reported that 
only a single patient, with both intrauterine and postnatal growth retardation has been 
found who had a deletion of the IGF1 gene (305).  To give a complete description of 
all the physiological functions of IGF-I are beyond the scope of this review. 
Therefore a brief background of IGF-I action will be given with specific emphasis on 
skeletal muscle.  
     IGF-I exerts some of its influence as an endocrine hormone circulating in the 
blood stream until reaching its target tissue. Unlike insulin, IGF-I in the circulation is 
bound by one of six known insulin-like growth factor binding proteins (IGFBPs) 
(133,135).  These binding proteins act as carriers of IGF-I to transport it out of 
circulation and prolong the half-life by protecting from proteolytic degradation.  In 
addition to their role in circulation, binding proteins are often expressed by target 
tissues where they act to regulate IGF-I function further.  Binding proteins have been 
shown to augment and attenuate IGF-I action depending on the target tissue (224). 
     Both gene knockout and transgenic animal studies have demonstrated the 




IGF-1 has been shown to stimulate satellite cell proliferation (43),increase amino acid 
uptake (177),suppress proteolysis (9), increase thymidine incorporation (85),stimulate 
myogenic differentiation (78),stimulate myogenesis (247), and enhance DNA 
accretion and growth (77).  Some recent studies have also shown that over-expression 
of IGF-I exclusively in skeletal muscle prevents EC uncoupling (298) and almost 
completely maintains skeletal muscle fiber specific force (89) in aged mice. Even 
though IGF-I  will stimulate both proliferation and differentiation of muscle cells in 
culture (218), unlike other mitogenic factors, it does not stimulate differentiation 
while it is stimulating proliferation (70).  There is a temporal separation between 
these two effects.  This could be due to the versatile intracellular signaling of the IGF-
I receptor. IGF-I treatment of muscle cells results initially in a proliferative response 
during which expression of myogenic factors are inhibited, followed by stimulation of 
differentiation accompanied by down regulation of proliferative signals (78). 
     Transgenic mice over expressing the IGF1 gene show enhanced myotube 
formation, as well as increased mRNA levels of the myogenic factors, Myo D and 
myogenin, and elevated mRNA for contractile proteins (47).  With a 47-fold increase 
in IGF-I, these mice showed  hypertrophy of all myofiber classes with no increase in 
body weight or circulating IGF-I  (47).  In addition, autocrine expression of IGF-I  
contributes to myotube formation in embryo (103).  Autocrine secretion of IGF-I 
facilitates muscle regeneration after injury in normal and hypophysectomized rats 
(131,263).  IGF1 mRNA levels and protein levels increase during muscle 
regeneration (158).  Viral mediated over expression of IGF-I in mouse skeletal 




the IGF-I expression prevents significant loss of the fastest and most powerful typeIIb 
muscle fibers observed  in  controls (15).  Transgenic mice over expressing IGF-I in 
muscle demonstrate protection from normal loss of muscle mass and strength during 
aging (192).  Additionally, these same transgenic mice display significantly improved 
muscle regeneration over control mice when muscle damage is induced via 
cardiotoxin (192).  The aged transgenic mice in this study display muscle 
characteristics similar to or better than younger control mice. 
     IGF-I is considered important for peripheral nervous system development and the 
IGF signaling system is considered a potential therapeutic target for the treatment of 
nerve injury and motor neuron diseases (266).  Muscle innervation may be improved 
in animals over expressing IGF-I.  In transgenic mice, skeletal muscle expressing 
IGF-I prevented aging alterations in the neuromuscular junction, preserved spinal 
cord motor neuron innervation of muscle, and decreased the loss of type IIb muscle 
fibers (178).  Additionally, Rabinovsky reported that transgenic mice over expressing 
IGF-I have accelerated muscle and motor neuron regeneration after sciatic nerve 
crush injury (219).  The regeneration or preservation of neural innervation will likely 
be a causative factor in preventing decline in muscle mass and function with age. 
Another recent study by Payne et al. (206) demonstrated that induced over expression 
of IGF-I in spinal cord motor neurons of ageing mice prevents muscle fibre specific 
force decline, a hallmark of ageing skeletal muscle. 
     Circulating IGF-I and exercise.  IGF-I is produced by various tissues including the 
skeletal muscle, however, 98% of the circulating form of IGF-I is produced in the 




Cappon et al. (38) first demonstrated that 10 min of above-lactate threshold cycle 
ergometer exercise studied in 10 subjects (age 22-35 yr) showed a small, but 
significant increase in circulating IGF-I levels very briefly after exercise.  This 
increase, however, was evident only until 20 minutes after exercise.  Several other 
studies have also investigated the relation of circulating IGF-I and exercise and have 
found an acute increase in circulating levels of IGF-I and IGFBP-3 after short-term 
high intensity dynamic exercise on a bicycle ergometer (11,297,248,65), but many 
studies failed to demonstrate any acute effect of short term exercise on IGF-I 
(248,129).  This difference may occur because the training intensity, type of training, 
age and fat mass of the subjects may affect the response of IGF-I to training (135).  
Nevertheless, ST studies did not show an increase in circulating IGF-I (150,199,202), 
but did change levels of potential modulators of IGF-1 action, including IGFBP-2, 
IGFBP-3, and acid labile subunit (202).  Other studies have demonstrated an increase 
in muscle IGF-I and muscle IGF1 mRNA levels with aerobic training (67,99) and 
eccentric exercise (10), respectively, but no change in circulating IGF-I levels. Thus, 
it appears that locally produced IGF-I has an important role in response to exercise in 
comparison to endocrine-derived IGF-I (294,83).  Further evidence for this comes 
from studies showing that transgenic over expression of IGF-I in skeletal muscles 
leads to significant hypertrophy without affecting circulating IGF-I levels (47), and 
mice lacking skeletal muscle IGF-IR have hypoplastic muscles, which in contrast to 
wild-type littermates are not stimulated by GH treatment (143).  A  recent  study by 
Mantheny et al.(173) utilized the liver IGF-I-deficient (LID) mouse model, in which 




IGF-I, to stress the importance of locally produced IGF-I.   In this study, 12 to 13 
month-old male LID and control (L/L) mice were subjected to 16 weeks of resistance 
training, and it was noted that the changes in the LID mice generally resembled those 
found in wild-type littermates.  Thus, training doubled the lifting capacity and 
increased hind leg muscle mass, IGF-I mRNA, and IGF-IR phosphorylation.  On the 
basis of these results, the authors concluded that normal muscle performance may be 
seen even in the setting of severe circulating IGF-I deficiency and that up-regulation 
of local IGF-I appears to be involved in compensatory growth of muscle in response 
to resistance training.  More surprisingly, the same authors (173) found a reduction in 
the intracellular signaling of GH, indicating that local increases in IGF-I are in fact 
GH independent.  Although this finding appears controversial, earlier studies in 
hypophysectomized rats and in rats made GH deficient by treatment with neutralizing 
GH-releasing hormone antibodies support that muscular IGF-I expression may not be 
strictly GH dependent (314).  
     On the basis of the current literature, it appears that the stimulatory impact of 
exercise on skeletal muscles is mediated by an augmented pituitary GH secretion, 
leading to an increased local IGF-I synthesis (83).  This hypothesis may explain why 
training studies generally have failed to link an improved muscle performance with 
changes in circulating IGF-I levels.  However, it should be acknowledged that a role 
of circulating IGF-I cannot completely be ruled out.  For instance, patients with GH 
insensitivity (ÈLaron syndrome) do respond to subcutaneous IGF-I by an increased 
muscle mass, although the response was less pronounced than the response observed 




     Thus future research needs to compare circulating versus locally produced IGF-I 
and their impact on skeletal muscles to elucidate the link between exercise, GH, and 
muscle hypertrophy.  In addition, future studies should investigate the time course for 
changes in muscle IGF1 gene expression and protein translation with exercise. 
Consequently, to gain more information, we need to optimize methodologies for the 
measurement of tissue IGF-I levels in humans. 
     Autocrine/paracrine role of IGF-I in aging muscle.  Circulating levels of GH and 
IGF-I, as well as muscle expression levels of IGF-I, decrease with age (292).  From 
30 to 40 years of age an almost linear decrease is seen with increasing age.  Also, in 
elderly people aged 50-100 years a continued decrease in IGF-I is noted, with roughly 
40% decrease by the age of 80.  This decline in circulating IGF-I levels is thought to 
be associated with poor muscle function, impaired physical performance and self 
reported difficulty in mobility tasks (149,37). 
     The IGF1 gene can express multiple isoforms, derived from alternative splicing, 
depending on the tissue of origin and the stimulus.  Alternative splicing is a complex 
mechanism by which exons are arranged in different combinations from pre-mRNA. 
It is an important and common process for generating protein diversity and regulating 
gene expression in higher eukaryotes.  The predominant circulating isoform of IGF-I, 
produced by the liver due to GH stimulation, has been termed IGF-1Eb and is 
produced by splicing out exon one and thus utilizes the exon two promoter.  This 





      The muscle expresses two known isoforms of the IGF1 gene when it is subjected 
to stretch or mechanical stimulation.  The first muscle isoform is termed IGF-1Ea 
(240).  Several different abbreviations have emerged for this isoform: L.IGF-1 and 
m.IGF-1 (100).  This isoform is initiated at the exon 1 promoter similar to the liver 
form, yet in 1 Ea, exon 5 is removed by alternative splicing.  Transgenic mice that 
over-express this isoform in skeletal muscle have been shown to have marked 
hypertrophy (192).  Additionally, older animals showed signs of protection against 
the normal loss of muscle mass associated with aging (192).  It was concluded that 
the over-expression of this isoform of IGF-I preserved muscle architecture and age-
independent regenerative capacity of muscle. 
     The second IGF1 isoform expressed in muscle, termed mechano-growth factor 
(MGF) or IGF-1Ec, is a splice variant resulting from a novel splice acceptor site in 
the intron preceding exon 6 and is generated in muscle subjected to stretch and 
overload (311).  Structurally, the MGF mRNA differs from its liver counterpart 
because of the presence of a 49-base pair insert on the carboxyl end of the protein, 
which is derived from exon 5 of the IGF1 gene. This isoform is not glycosylated, 
therefore, it is expected to have a shorter half-life than the liver IGFs and is therefore 
likely to be designed to act in an autocrine/paracrine, rather than in a systematic 
fashion.  As a result, it binds to its own muscle-specific binding protein, in the 
interstitial tissue spaces.  Animal studies have shown significant up regulation of 
MGF with muscle stimulation (176,311).  Other studies have shown that locally 
produced IGF-I can stimulate muscle hypertrophy through activation of satellite cells 




studies have shown an increase in muscle IGF-I with a single bout of resistance 
exercise (10,258,216).  However, attenuation of MGF induction has been observed in 
aged human muscle after resistance exercise (102).  Thus, it has been postulated that  
sarcopenia may in part be due to failure to generate an isoform of IGF-I  that is 
necessary to initiate the remodeling of muscle, i.e. to stimulate satellite cell activation 
and proliferation (87,88).  Barton et al. (14) recently expanded on this concept by 
showing that adeno-associated virus expression of IGF-I Ea and Eb promoted muscle 
growth in 2-4 month old rats, whereas in 6-month old rats, IGF-I Ea was an effective 
hypertrophic agent but IGF-I Eb was not.  These results suggested that the ability to 
accumulate Eb was attenuated with increased age of the rat or that there was age 
associated resistance to Eb.  However, Hameed et al. did report ~170% increase in 
MGF with 5 weeks of ST and no increases in circulating IGF-I in elderly men. 
     Results from previous studies clearly show that ST induces local expression of 
IGF-I and it is likely that IGF-I is mediating many of the hypertrophic effects 
observed in skeletal muscle. Yet as previously mentioned, there is significant 
variability seen in the strength and hypertrophic response of muscle to ST. 
Additionally, the increases in IGF1 mRNA that occur in response to resistance 
exercise have been shown to range from 2-864% (102), and a variation for IGF-I 
increase with ST of ~137% has been observed in the elderly (258,101).  These results 
suggest that genetics could be affecting this response.  Indeed, studies have shown 
that circulating levels of IGF-I are almost completely under genetic control in healthy 
twin children and the variability in circulating levels in the elderly is estimated to be 




examined the heritability of IGF1 muscle expression.  An autosomal genome wide 
search for genes related to fat free mass (FFM) and its changes after exercise training 
revealed that a polymorphism in the IGF1 promoter region displayed significant 
linkage with changes in FFM (42).  Additionally, this same polymorphism was shown 
to be associated and in linkage with baseline FFM and with the change in FFM 
resulting from aerobic exercise training (267).  More recently, this polymorphism has 
been shown to be associated with change in muscle strength and muscle quality with 
ST in older men and women (147,104). 
     IGF1 CA dinucleotide repeat polymorphism.  The IGF1 polymorphism identified 
in the genome wide scan and most association studies is the CA dinucleotide repeat 
polymorphism near the promoter region of the IGF1 gene in humans (299).  A similar 
CA repeat near a gene promoter has been shown to alter gene expression in rats and 
humans (2,239).  Repeat sequences account for at least 50% of the entire human 
genome sequence.  Commonly defined as a perfect or near- perfect sequence repeat of 
1-5 bases, microsatellites are found in tandem repeat units of 10-30 repeats. 
Alternating purine-pyrimidine nucleotides (i.e. CA) are one type of microsatellite 
and, other than SNP’s, microsatellites are the most variable component of the human 
genome.  Three percent of the human genome consists of microsatellite repeats of 
which CA dinucleotides are the most common making up 0.5% of the human genome 
(152).  The biological function of repeat units has not been completely defined but a 





      A proposed function of some microsatellites is to regulate gene transcription. A 
disproportionate amount of these repeats are found in the promoter regions of genes 
in the human genome (249).  This along with their known ability to alter gene 
transcription and the binding affinity of nuclear transcription factors make them areas 
of likely functional importance (139).  Alternating purine-pyramidine microsatellites 
in promoter regions have been reported to be involved in regulation of gene 
expression (138,196,249).  Khashnobish et al. (142) were the first to report in vivo 
regulation of gene expression by a CA repeat unit of  varying lengths in Podospora 
anserine.  Their results demonstrated that the number of CA repeats positively affects 
gene expression.  In a study by Peter et al. (209), it was shown in vitro that a CA 
repeat polymorphism commonly found in the human population can affect gene 
expression depending on the length.  This was the first study to show that 
microsatellite length polymorphisms that are commonly found in normal human 
population can alter gene expression.  Furthermore, they demonstrated that the CA 
repeat element might serve as a binding site for specific nuclear regulatory proteins. 
Regulation of gene expression by varying of CA repeats in the promoter region, as 
mentioned, or in introns has been shown to affect gene expression in rats and humans 
(2,45,239). 
     The microsatellite polymorphism near the promoter region of the IGF1 gene is 
typically between 16 and 22 CA repeats and this polymorphism is commonly referred 
to by the base pair length of the amplified DNA fragment (e.g. 192 bp).  The 192 
allele (19 CA repeats at nucleotide position 1087-1127 in the human IGF1 DNA 




promoter polymorphism has been investigated in various contexts.  Genotyping of 
this polymorphism is typically separated into three groups: 192 homozygotes, 192 
heterozygotes, and non-carriers of the 192 allele.  It has not been determined whether 
the 192 polymorphism is causally related to changes in IGF1 function, yet, the 192 
allele is the most prevalent allele in the majority of the populations studied to date.  A 
study by Vaessen et al. (288) reported that in a population-based sample, 88.4% of 
the subjects were homozygous or heterozygous for the 192-bp allele, suggesting that 
this the wild-type allele from which all other alleles originated.   Although this 
polymorphism has not been proven to be functional, it has been proven to be a 
potential marker for disease-related phenotypes and possibly IGF1 expression levels, 
as well as it has been previously shown to influence muscle strength and muscle 
quality in response to ST in older individuals (147,104). 
     Rosen et al. (236) first implicated this polymorphism with serum levels of IGF-I 
and bone mineral density in a study examining older men and women.  It was 
reported that 192 homozygotes had lower blood levels of IGF-I and in a group of 
older men,192 homozygotes made up a disproportionately large percentage of those 
with idiopathic osteoporosis (236).  Since this report other groups have investigated 
the influence of the 192 allele on circulating IGF-I levels with some studies showing 
decreased (80,229), increased (144,183,231,288), or no difference unless combined 
with oral contraceptive use (132,313).  There have been other additional reports of the 
192 allele showing no association with IGF-I blood levels or any measured phenotype 
(4,56).  The study by Delellis et al. (56), examined 250 adult women for association 




examined older and younger men for association of blood levels of IGF-I and the 
IGF1 microsatellite polymorphism.  It was concluded by these studies that the 192 
polymorphism is unlikely to be associated with IGF1 function.  In contrast a more 
recent study in 163 premenopausal women, reported that the number of 19 alleles at 
the 5’ polymorphism was associated with lower circulating levels of IGF-I ( P = 0.02) 
and explained 5% of the variance in IGF-I levels (71).  Similarly, recently Hoyo et 
al.(118) conducted a study to determine the predictors of serum IGF-I and IGFBP3 
levels and the results revealed that in African-americans, 17% of the variation in 
serum IGF-I levels were explained by cigarette smoking and carrying the IGF1 
(CA)19 repeat allele. 
     If the 192 allele itself is not functional it would at least seem to be a valid marker 
for phenotypes related to IGF-I expression.  The possibility exists that the 192 
polymorphism is in linkage disequilibrium with a functional polymorphism in the 
IGF1 gene. Currently there are very few studies that have examined this 
polymorphism in relation to skeletal muscle phenotypes, with none that has examined 
its association with muscle power.  Due to the substantial loss of muscle power and 
IGF-I expression with advancing age and the close association between muscle power 
and performance of functional abilities, this association in older adults could have 
important clinical significance. 
      Although results are inconclusive for the effect of the 192 polymorphism on IGF-I 
levels, it seems possible that the IGF1 192 polymorphism may affect skeletal muscle-
related phenotypes because of previous results showing positive associations of this 




quality with ST (147,104).  However, in all studies reported, the association was 
studied between this polymorphism and total IGF-I in circulation. Considering that 
circulating IGF-I levels may not reflect the IGF-I levels present locally in skeletal 
muscle tissue, future studies should study the relation of this polymorphism with 
transcription and protein levels of IGF1 in the muscle, to better understand the 
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